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Abstract		
The	pursuit	of	sensitive,	non-invasive,	and	cost	efficient	diagnostic	tools	for	early	stage	disease	detection	have	led	to	the	development	of	sophisticated	biosensor	technologies	for	proteomic	studies.	As	these	markers	increase	in	complexity,	the	role	of	support	substrates	grows	increasingly	important.	Limitations	in	existing	support	substrates	include	the	potential	for	increased	sensitivity,	binding	specificity,	and	bio-stability.	Ideal	support	substrates	need	to	provide	biocompatible	and	bioresistant	surfaces,	that	offer	high	surface	areas	for	binding,	and	enables	the	incorporation	of	diverse	chemistries.	The	use	of	peptoids	as	the	basis	for	the	deposition	of	uniform	microsphere	coatings	offers	a	mean	to	the	attainment	of	such	characteristics.	Specifically,	it	enables	for	the	utilization	of	its	unique	characteristics,	namely,	ease	of	synthesis	and	highly	customizable	side	chain	chemistries,	in	order	to	create	a	robust,	biocompatible	surface.		
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1.	Introduction	
Although	knowledge	of	different	types	of	cancer	and	their	progression	has	grown	remarkably	in	the	last	decades,	progress	in	the	efforts	has	in	large	been	hampered	by	the	technology	to	detect	them	at	an	early	stage.	This	difficulty	stems	from	the	fact	that	the	diagnosis	of	a	disease	cannot	be	considered	analogous	to	its	detection.	Diagnosis	predominantly	follows	the	recognition	of	symptoms,	and	many	of	those	initial	symptoms	are	often	indicative	of	a	number	of	diseases	with	similar	features,	rather	than	specific	to	the	one	responsible.	Most	importantly	however,	cancer	diagnosis	often	occurs	too	late,	as	symptoms	manifest	themselves	once	tumors	are	considerably	large	and	the	disease	consequently	widespread.		
Mortality	rates	in	cancer	increase	with	disease	progression.	For	this	reason,	it	is	at	its	incipient	stages	of	development	that	the	therapeutic	treatment	of	cancer	presents	its	greatest	potential.	However,	these	early	stages	are	often	asymptomatic,	resulting	in	delayed	diagnoses	of	more	advanced	stages	for	which	treatment	is	found	often	ineffective	[1].	Data	from	the	Surveillance	Epidemiology	and	End	Results	(SEER)	Program	of	the	National	Cancer	Institute	demonstrates	the	sharp	contrast	that	exists	in	areas	where	tumor	growth	can	be	more	easily	observed,	and	hence	detected,	as	compared	to	internal	organs	where	it	is	much	more	difficult	[2].	While	the	5	year	survival	rate	in	skin	cancer	(91.5%)	and	breast	cancer	(89.4%)	paints	a	much	more	optimistic	outlook,	lung	cancer	(17.4%)	and	pancreatic	cancer	(7.2%)	drop	a	sobering	dose	of	reality	(http://seer.cancer.gov)	[3].	The	identification	of	cancer	by	pathological	techniques	is	reliant	on	the	morphologic	assessment	of	tumor	tissue.	While	this	method	is	suitable	for	the	identification	of	tumors	
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that	occur	at	certain	accessible	areas	(cervix),	this	same	type	of	assessment	is	not	feasible	at	other	less	accessible	regions	(ovaries),	which	hence	hold	much	higher	rates	of	mortality	[4].	While	crucial	for	the	current	prognosis	of	cancer,	these	techniques	unfortunately	fall	short	in	providing	the	basis	for	the	development	of	a	technology	that	would	allow	for	early	detection	[5].		
Early	detection	decreases	the	economic	costs,	extensiveness	of	the	treatment,	and	mortality	associated	with	the	disease	[6].	The	value	of	diagnostic	technologies	is	intrinsically	related	to	accuracy	and	stage	at	which	they	are	able	to	identify	a	disease.	Disease	identification	needs	the	existence	of	sensitive	assays	that	can	detect	molecular	changes	associated	with	the	onset	of	the	disease	with	high	specificity.	Early	detection	requires	the	screening	of	asymptomatic	populations	in	a	minimally	invasive	manner	and	with	small	sample	volumes.	Biomarker-based	technologies	offer	promising	means	for	the	attainment	of	these	goals	[4].	
1.1.	Biomarkers	
Over	the	last	decades,	there	has	been	an	enormous	effort	to	develop	sensitive	disease-specific	assays	that	can	assist	in	therapeutic	decision	[1].	Biomarkers	are	molecular	indicators	of	a	physiological	status,	and	as	a	result	can	be	assayed	to	provide	information	on	the	state	of	a	biological	process	[7].	The	use	of	biomarkers	is	integral	to	cancer	research	because	of	the	unique	association	genomic	changes	in	cancer	cells	have	with	the	progression	of	the	disease	[1].	Cancer	biomarkers	reflect	genotoxicity,	hyperproliferation,	hyperplasia,	inflammation,	mutations,	altered	patterns	of	gene	and	protein	expression,	promoter	methylation,	and	enzymatic	changes	produced	by	the	disease	or	the	host	system	
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in	response	to	the	disease	[5]	[7].	Understanding	these	changes	as	natural	identifiers	of	disease	progression	will	allow	for	the	discovery	of	new	biomarkers	for	(i)	early	detection,	(ii)	diagnosis,	(iii)	prognosis	of	high-risk	individuals,	(iv)	response	to	treatment	and/or	(v)	recurrence	of	the	disease	[8].	
Progress	in	proteomic	technologies	have	led	to	the	discovery	of	novel	biomarkers	through	the	assessment	of	proteome	profiles	in	disease	states	[9].	In	contrast	to	the	genome,	which	is	rather	more	of	a	constant	entity,	the	proteome	represents	a	dynamic	compilation	of	diverse	proteins	that	vary	among	different	individuals,	cell	types,	and	pathophysiological	conditions	[10].	While	the	genome	comprises	the	genetic	makeup	of	each	cell,	it	provides	little	information	about	their	structure,	interactions,	modifications,	cellular	localization,	activities,	biological	function,	and,	potential	involvement	in	the	carcinogenic	process	[11].	In	fact,	gene	activity	and	protein	abundance	show	no	reliable	correlation	[12].	The	biological	roles	of	proteins	are	determined	by	post-translation	modifications	and	interactions	such	as	glycosylation,	phosphorylation,	cleavage,	crosslinking,	oxidation	or	reduction,	and	lipid	attachment	[13].	The	complexity	of	these	modifications	has	lead	to	the	realization	that	protein	dynamics	cannot	be	probed	using	genetics	and	DNA-based	methods	[14].	Protein-based	approaches	provide	a	natural	platform	for	these	studies.	They	are	based	on	the	identification	of	altered	protein	expression	levels	in	disease	states	[15]	[16].	Antibody-based	arrays	are	also	often	utilized	for	diagnosis.	Antibodies,	being	natural	binders	of	proteins,	provide	a	means	to	compare	and	quantify	protein	levels	in	health	and	disease	[17].	Antibody	platforms	have	been	developed	on	monoclonal,	polyclonal	and	recombinant	antibodies	[13]	[18]	[19]	[20]	[21]	[22]	[23]	[24]	[25].	Antibodies	are	widely	utilized	in	protein	detection	because	of	the	high	specificity	that	is	required	in	order	to	
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identify	a	target	[26].	Additionally,	the	relative	structural	uniformity	of	antibodies	allows	for	the	utilization	of	single	support	surfaces.		
Changes	in	post-translational	modifications	of	protein	structures	have	important	roles	in	disease	progression,	and	thus	if	profiled	correctly	offer	valuable	information	associated	to	the	disease.	Glycosylation	is	one	of	many	post-translational	modifications,	prevalent	in	over	50%	of	proteins	[27].	Glycans	are	involved	in	recognition,	adherence,	motility,	and	signaling	processes	[28]	[29].	The	potential	as	biomarkers	is	reflected	by	the	occurrence	of	cancer-associated	glycans	resultant	from	oncogenic	altered	glycosylation.	Cancer-associated	glycans	are	predominantly	located	on	the	surface	of	cells,	and	therefore	ideal	targets	for	detection	[30].	Glycans	have	been	screening	in	human	serum	for	diagnostic	purposes	[31]	[32]	[33]	[34]	[35]	and	utilized	for	malignancy-identification	for	breast	cancer	[35]	and	Hodgkin’s	lymphoma	[36].		
1.2.	Microarrays	
While	advances	in	technology	continue	to	accelerate	the	discovery	of	potential	biomarkers	[37]	[38]	[39],	assessment	of	their	true	value	for	the	screening	of	complex	disease	lags	behind.	In	fact,	the	approval	rate	of	new	clinical	biomarkers	is	in	decline	[37].	A	major	obstacle	hampering	biomarker	validation	is	the	intrinsic	molecular	heterogeneity	that	exists	across	diverse	populations	and	tumor	tissues.	To	overcome	this	large	variability,	validation	technologies	need	to	reproducibly	analyze	thousands	of	samples	to	effectively	assess	assay	performance	[40].	Enzyme-linked	immunosorbent	assay	(ELISA)	microarray	technology	can	analyze	a	profile	of	biomarkers	in	parallel	and,	thus,	has	the	sensitivity	and	specificity	necessary	to	accelerate	the	validation	of	clinical	biomarkers	[41]	[42].		
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The	concept	of	the	‘microspot’	assay	was	introduced	by	Ekins	under	the	fundamental	premise	that	miniaturization	would	allow	for	the	detection	of	analytes	with	higher	sensitivity	than	those	of	conventional	macroscopic	immunoassays	[43]	[44].	ELISA	microarray	technology	was	developed	in	early	2000	[17]	by	combining	protocols	and	instrumentation	for	DNA	microarrays	and	96-well	plate	ELISA	[45],	yielding	a	robust	and	automated	platform	of	unmatched	high-throughput	sensitivity	and	reproducibility	[46].	Antibody	microarray	technology	has	been	utilized	for	the	non-invasive	detection	of	disease-specific	analytes	in	bodily	fluids	(serum,	plasma,	urine,	tears)	and	tissues	extracts	[47]	for	leukemia	[48],	breast	cancer	[49]	[50]	[51]	[52],	prostate	cancer	[53],	pancreatic	cancer	[54]	[55],	lung	cancer	[56]	[57]	[58],	bladder	cancer	[47],	colorectal	cancer	[59]	[60],	cystic	fibrosis	[61],	primary	Sjogren's	syndrome	[62],	psoriatic	arthritis	[63],	as	well	as	congestive	heart	failure	[64].	
1.2.1.	Enzyme-Linked	Immunosorbent	Assay	(ELISA)	Microarray	
Enzyme-linked	immunosorbent	assay	(ELISA)	microarray	technology	has	emerged	as	a	strong	platform	for	the	analysis	of	biomarkers.	Advantages	of	this	platform	are	associated	to	the	miniature	nature	of	its	design,	which	allows	for	the	cost-effective	and	efficient	parallel	screening	of	small	volumes	of	precious	clinical	samples	and	expensive	antibodies	in	a	high-throughput	manner,	thus	enabling	the	study	of	large	populations	of	samples	necessary	for	the	identification	and	validation	of	biomarkers	[45].	In	addition,	the	assays	allow	for	the	quantitative	measurement	of	multiple	proteins	in	complex	biological	fluids	over	a	large	concentration	range	with	high	sensitivity	and	specificity	[65].	Furthermore,	its	similarity	to	ELISA	protocols	used	routinely	in	clinical	laboratories	facilitates	assay	transfer	
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from	the	laboratory	to	clinical	settings	[66].	
The	capability	to	analyze	multiple	proteins	in	parallel	offers	many	benefits.	Aside	from	practical	benefits	(time,	cost,	reagent	consumption),	parallel	measurements	are	of	great	scientific	interest	[13].	Multiplex	studies	allow	for	the	screening	of	biomarkers	to	reveal	associations	in	proteins	and	disease	states.	Proteins	interact	in	complex	networks	and	often	have	overlapping	or	complementary	functions.	Multiplex	studies	thus	provide	experimental	conditions	that	can	portray	a	much	more	meaningful	picture	of	a	biological	state	[13].	Furthermore,	multiplex	studies	can	increase	the	sensitivity	and	specificity	of	disease	diagnostics,	and	thus	result	in	fewer	false	positives	and	false	negatives	as	compared	to	single	markers	[67].	
The	miniaturized	design	of	these	antibody	microarrays	(<1	cm2)	is	based	on	the	immobilization	of	minute	amounts	of	antibodies	(~	400	pL)	onto	a	solid	support	in	an	ordered	pattern,	a	microarray	(Figure	1.1.)	[18].	These	antibodies	serve	to	bind	protein	analytes	onto	the	surface.	The	microarrays	are	incubated	with	small	amounts	of	sample	(~	20	μL)	and	then	generally	tagged	for	fluorescent	detection.	An	enzyme-dependent	signal	amplification	step,	such	as	biotin	tyramide,	is	often	used	to	reach	sensitivities	in	the	fM	range,	and	allow	for	the	detection	of	low-abundant	(pg/ml)	protein	analytes	[18]	[51]	[68]	[69].	
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	Figure	1.1.	Schematic	diagram	of	sandwich	ELISA	microarray.		Antibody	microarrays	are	often	performed	based	on	two	distinct	experimental	constructs:	label-based	assays	or	sandwich	assays	[67].	Label-based	assays	rely	on	the	capture	of	tagged	protein	analytes	for	detection.	This	format	allows	the	co-incubation	of	different	tagged	protein	analytes.	Co-incubation	makes	analytes	compete	for	binding.	Competitive	assays	have	some	advantages	over	non-competitive	assays	in	terms	of	linearity	of	response	and	dynamic	range	[70]	Sandwich	assays	rely	on	the	presence	of	a	second	‘detection’	antibody	that	binds	to	the	same	antigen	as	the	immobilized	‘capture’	antibody,	but	with	affinity	for	a	different	site	(Figure	1.2.).	This	detection	antibody	is	typically	biotinylated	for	subsequent	measured	using	streptavidin	labeled	with	a	fluorophore	or	enzyme	[13].	The	use	of	matched	antibody	pairs	to	target	each	antigen	increases	assay	sensitivity	and	specificity	[45].	Sandwich	assays	are	non-competitive	as	they	permit	the	incubation	of	only	one	sample.	Non-competitive	assays	have	sigmoidal	binding	responses	of	narrower	dynamic	ranges	[67].	
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	Figure	1.2.	Schematic	demonstrating	the	difference	between	labeled	based	assays	and	sandwich	based	assays.			
1.2.2.	Specificity	and	Cross-Reactivity	
Sensitivity	refers	to	the	percentage	of	individuals	with	a	disease	who	test	positive	for	a	marker	in	question,	while	specificity	refers	to	the	percentage	of	individuals	without	disease	who	test	negative	for	the	same	marker	[8].	The	lower	the	sensitivity,	the	more	often	individuals	with	the	disease	will	pass	undetected,	and	the	lower	the	specificity,	the	more	often	individuals	without	the	disease	will	test	positive	[71].	A	major	challenge	in	the	validation	of	cancer	biomarkers	is	high	variability	and	low	incidence	of	specific	cancers	across	populations	[45].	As	a	result,	assays	of	very	high	sensitivity	and	specificity	are	required.	Otherwise,	biomarkers	are	unable	to	distinguish	individuals	both	with	and	without	the	disease	[45].	A	number	of	potential	biomarkers	do	not	progress	beyond	this	point	for	this	very	reason	[60].	Similarly,	even	many	of	the	best	biomarkers	presently	available,	often	fall	short	in	meeting	those	expectations,	as	is	the	case	with	prostate	specific	antigen	(PSA).	As	a	biomarker	for	prostrate	cancer	PSA	exhibits	sensitivities	greater	than	90%,	however	has	specificities	of	only	25%.	This	high	incidence	of	false	positives	results	in	a	large	number	of	unnecessary	and	often	invasive	biopsies	that	take	a	toll	in	the	lives	of	
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people	that	extends	far	the	financial	one	[72]	[73]	[74]	[75].	In	a	similar	manner,	the	biomarker	for	breast	cancer	CA15.3	only	reaches	sensitivities	of	23%	and	specificities	of	69%	and	as	a	result	is	limited	to	monitoring	advanced	stage	breast	cancer	responses	to	treatment	or	recurrence	[8].	The	analysis	of	multiple	protein	profiles	rather	than	reliance	on	single	biomarkers	offer	the	potential	to	achieve	the	sensitivity	and	specificity	that	is	required	the	early	detection	[7].	
Although	sandwich	assays	are	known	for	their	high	sensitive	and	specificity,	in	multiplex	studies	great	care	needs	to	be	taken	in	order	to	ensure	no	cross-reactivity	or	interference	exists.	While	often	negligible	in	arrays	of	limited	complexity,	large-scale	studies	screening	libraries	of	antibodies	against	a	number	of	potential	targets	increase	the	prevalence	of	cross-reactive	binding.	Cross-reactivity	often	occurs	due	to	sequence	and/or	structure	similarity	of	binding	sites.	Monoclonal	antibodies	tend	to	be	more	susceptible	to	cross-reactions	than	polyclonal	antibodies,	for	which	effects	are	dissipated	by	the	heterogeneity	of	the	antibody	population	[4].	In	addition,	non-specific	interactions	can	render	proteins	inactive,	often	just	by	making	binding	sites	inaccessible	through	steric	hindrance.	Efforts	to	further	develop	the	microarray	technology	as	a	result	are	directed	toward	the	reduction	of	cross-reactivity	between	assays	[76].	
1.2.3	Surface	and	Attachment	
One	of	the	main	challenges	in	the	development	of	protein	and	antibody	microarrays	is	the	immobilization	of	molecules	of	diverse	structures	and	characteristics	onto	a	solid	support	in	a	manner	that	also	maintains	their	innate	binding	properties.	Surface	chemistries	and	immobilization	procedures	are	crucial	for	the	optimal	performance	of	microarray	
10		
platforms,	as	is	evident	by	the	large	number	of	slide	surfaces	commercially	available	[77].	Ideal	surfaces	for	ELISA	microarray	need	to	provide	not	only	strong	attachment	of	the	immobilized	antibodies,	but	also	retain	their	inherent	activity	and	display	high	binding	capacities,	signal-to-noise	ratios,	and	reproducibility	across	all	chips,	slides,	and	experiments	[78].	Additionally,	the	high-throughput	nature	of	the	platform	requires	supports	to	be	robust	and	retain	high	levels	of	specificity	and	sensitivity	through	rigorous	processing	conditions	and	prolonged	storage	periods.	
Globular	proteins	usually	consist	of	a	hydrophobic	core	and	hydrophilic	surface.	Immobilization	onto	hydrophobic	surfaces	destabilizes	protein	structure,	in	essence	turning	its	inside	out,	and	as	a	result	rendering	it	inactive	[79].	Antibodies	in	particular	need	to	maintain	their	native	confirmation	upon	immobilization	in	order	to	retain	binding	specificity	[80].	In	addition,	unlike	DNA,	which	have	a	uniform	negatively	charged	phosphate	backbone	exterior	that	allows	for	its	relatively	facile	immobilization	onto	oppositely	charged	surfaces,	protein	surface	charges	are	very	diverse,	and	consequently	often	require	complex	surface	chemistries	and	immobilization	procedures	[77].		The	challenge	lies	in	designing	a	microarray	support	that	accommodates	proteins	of	varying	characteristics	in	a	way	that	provides	a	non-denaturing	environment	that	preserves	the	active	form	of	the	protein.	
There	are	a	number	of	immobilization	strategies	and	solid	supports	currently	in	existence	[81]	[82]	[83]	[84]	[85]	[86].	However,	microarray	surfaces	can	in	general	be	broadly	categorized	into	two	main	types:	two-dimensional	surfaces	and	three-dimensional	surfaces.	While	two-dimensional	surfaces	allow	for	the	direct	attachment	of	proteins	to	the	
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surface,	three-dimensional	surfaces	retain	proteins	within	a	matrix	(Figure	1.2.).	Glass	slides	are	widely	preferred	as	two-dimensional	solid	support	platforms	because	of	their	inherent	low	fluorescence	[65]	[87]	[88]	[89]	[90]	[91].	However,	in	order	to	facilitate	attachment,	glass	slides	have	been	functionalized	with	a	variety	of	different	chemical	modifications.	Two-dimensional	surfaces	include	aldehyde	[89]	[92],	aminosilane	[77]	[93]	[94],	epoxysilane	[93]	[94],	mercaptosilane	[94],	polystyrene	[77],	and	poly-L-lysine	coated	slides	[65].	These	surfaces	immobilize	proteins	through	electrostatic	and	covalent	interactions.	Covalent	attachment	is	often	achieved	through	cross-linking,	via	amine	or	thiol	groups.	While	these	surfaces	offer	a	number	of	advantages,	due	predominantly	to	the	unique	combination	of	both	strong	attachment	and	low	coefficients	of	variation,	they	also	present	distinct	disadvantages,	including,	high	rates	of	evaporation	and	close	contact	with	the	surface,	which	can	affect	protein	structure	[24].		
	Figure	1.3.	Schematic	demonstrating	the	three-dimensional	surfaces,	two-dimensional	surfaces,	and	other	more	specialized	microarray	surfaces.	Three-dimensional	surfaces	include	polyacrylamide	[89]	[95],	agarose	[90]	and	nitrocellulose	gels	[96]	[97]	[98]	[99]	[100]	[101],	as	well	as	poly(vinylidene	fluoride)	
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(PVDF)	membranes	[102]	[103].	These	surfaces	immobilize	proteins	through	physical	adsorption,	retaining	them	within	its	structure	via	hydrophobic	interactions.	These	matrices	provide	a	more	protein	friendly	environment	that	preserves	their	native	conformation,	allowing	for	a	more	optimal	surface	for	binding,	and	hence	higher	binding	capacities	and	signal	intensities	[104].	However,	while	these	surfaces	perform	well	in	terms	of	limits	of	detection,	as	a	whole,	they	display	much	higher	coefficients	of	variation	[77].	Background	fluorescence	can	also	be	matter	of	concern,	and	surfaces	often	require	much	more	involved	pretreatment	and	blocking	procedures.	Additionally,	because	of	the	more	complex	nature	of	their	three-dimensional	structure,	permeability	can	also	considerably	complicate	the	kinetics	of	the	protein	interactions,	due	primarily	to	the	slow	rates	of	protein	diffusion	[98].		
	Figure	1.4.	Schematic	representation	poly-L-lysine	coated	microarray	slides.	
There	exist	other	more	specialized	surface	chemistries	that	are	more	difficult	to	categorize	as	they	combine	characteristics	of	the	two.	While	they	do	not	provide	a	three-dimensional	structure	within	which	proteins	could	be	retained,	these	surfaces	cannot	be	considered	to	
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be	two-dimensional	either	as	the	do	incorporate	some	sort	of	supra-molecular	surface	assembly	for	attachment	[24].	Surfaces	which	these	characteristics	include	avidin	[105],	streptavidin	[84],	nickel	[92]	dendrimer	[106]	[107],	or	polyethylene	glycol	(PEG)	slides	[108].	These	surfaces	immobilize	proteins	through	the	covalent	attachment	of	epoxy	and	specialized	affinity	groups.	Affinity	binding	improves	coupling	and	lessens	direct	surface	contact	destabilization.	Avidin	and	streptavidin-coated	surfaces	are	for	these	reasons	widely	used	for	the	immobilization	of	biotinylated	capture	molecules.	In	a	similar	manner,	histidine	tags	facilitate	attachment	on	nickel-coated	surfaces.	Dendrimers	increase	the	density	of	functional	surface	groups	to	optimize	protein	immobilization.	PEG	layers	prevent	direct	surface	contact	and	reduce	background	binding	lessening	the	need	of	blocking	reagents.	
High-throughput	demands	in	protein	microarrays	require	the	selection	and	development	of	optimized	support	surfaces	that	allow	for	more	generally	applicable	and	direct	immobilization	procedures.	While	high	binding	affinities	are	imperative	in	preventing	antibody	loss	and	ensuring	surface	attachment	withstands	processing	conditions,	which	involve	rather	extensive	wash	procedures.	The	reality	of	antibody	immobilizations	is	that	functional	loss	can	occur	as	a	result	of	relatively	passive	interactions,	as	well	as	more	structurally	intrusive	chemical	linkages.	Angenendt	et	al.	[77]	compared	the	limits	of	detection,	coefficients	of	inter-	and	intra-chip	variation,	and	storage	characteristics	for	different	commercially	available	slide	variations.	While	no	particular	slide	took	all	areas,	in	terms	of	overall	array	performance,	poly-L-lysine	and	aldehyde	slides	displayed	the	best	signal	uniformity	and	signal-to-noise	ratios.	Kusznezow	et	al.	[94]	studied	a	number	of	variables	affecting	antibody	microarrays,	including	surface	modifications,	cross-linking	
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strategies,	spotting	buffer	compositions,	blocking	reagents,	antibody	concentrations,	and	storage	conditions.	For	surfaces	where	antibodies	were	not	covalently	attached,	poly-L-lysine	slides	displayed	superior	signal-to-noise	ratios,	despite	having	rather	relative	low	signal	intensities.	Nitrocellulose	surfaces	on	the	other	hand	exhibited	the	highest	signal	intensities,	however	as	with	other	three-dimensional	surfaces,	also	produced	high	background	signals.	For	surfaces	where	antibodies	were	covalently	attached,	cross-linked	silane	surfaces	performed	best,	displaying	good	sensitivity	and	signal-to-noise	ratios.	Evaluating	similar	surfaces,	Servoss	et	al.	[78]	found	that	as	a	whole,	three-dimensional	slide	surfaces	have	higher	background	fluorescence	than	two-dimensional	slide	surfaces,	due	predominantly	to	the	increased	difficulty	these	more	complex	surfaces	present	to	efficiently	block	and	wash	the	surface.	Additionally,	no	significant	drop	off	was	observed	when	assessing	antibodies	immobilized	on	non-covalent	surfaces	as	compared	to	those	attached	covalently.		
1.3.	Poly-N-Substituted	Glycines	(Peptoids)	
Inspired	by	natural	polymers,	the	work	of	chemists	and	chemical	engineers	has	focused	in	the	development	of	synthetic	polymeric	materials	that	are	able	to	mimic	some	of	the	fundamental	molecular	features	that	allow	for	the	diverse	array	of	functional	structures	nature	so	elegantly	creates	with	just	a	set	of	monomeric	sequences	and	interactions	[109].	Polypeptides	confer	proteins	a	myriad	of	unique	functional	properties,	providing	for	example,	binding	and	catalytic	sites	that	together	hence	enable	molecular	recognition.	However,	as	biocompatible	materials	peptides	present	a	major	drawback,	they	are	susceptible	to	in	vivo	proteolitic	degradation,	and	as	a	result	are	limited	in	their	potential	
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for	biomedical	and	therapeutic	applications	[110].	Efforts	to	overcome	these	limitations	have	led	to	the	design	and	development	of	innovative	peptidomimetic	oligomers	[111]	[112]	[113]	[114]	[115]	[116].	Synthetic	polymer	analogs	exploit	structural	similarities	in	order	to	allow	for	the	mimicry	of	bioactive	functionalities.	These	bioactive	roles	are	often	determined	by	the	unique	ability	of	peptides	to	self-assemble	into	complex,	sequence-specific	three-dimensional	secondary	structures	[117].	Specific	peptidomimetic	oligomers,	commonly	referred	to	as	foldamers	[118],	which	in	addition	to	the	mimicry	of	primary	structure	display	well-defined	secondary	structures,	are	therefore	of	great	interest.	
Oligomeric	N-substituted	glycines	(peptoids)	are	a	form	of	bioinspired	peptidomimetic	polymers	whose	backbone	structure	closely	resembles	that	of	peptides,	but	have	side	chains	appended	to	the	amide	groups	rather	than	the	α-carbons	(Figure	1.5.).	This	structural	modification	prevents	proteolytic	degradation,	making	peptoids	a	promising	alternative	as	biocompatible	materials	for	therapeutic	applications.	However,	this	modification	also	removes	the	presence	of	backbone	amide	hydrogens,	critical	for	secondary	structure,	at	least	in	terms	of	allowing	for	the	formation	of	the	same	type	of	hydrogen	bond	linkages	that	stabilize	beta	sheets	and	helices	in	peptides.	Despite	these	limitations,	secondary	structures	such	as	turns,	loops,	and	helices	that	in	turn	allow	for	the	formation	of	supramolecular	assemblies	can	be	induced	in	peptoids	upon	the	addition	and	proper	placement	of	specific	side	chains	[119].	The	inclusion	of	chiral	aromatic	side	chains	has	been	demonstrated	to	incite	the	formation	of	helical	secondary	structures	reminiscent	of	polyproline	type	I	helix	[120],	stabilized	primarily	through	steric	and	electrostatic	interactions	[117].	Circular	dichroism	(CD)	spectra	of	these	peptoids	closely	resemble	the	spectra	of	peptide	α-helices	[121].	
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	Figure	1.5.	Structural	comparison	of	peptide	and	peptoid	molecules.	
Like	peptides,	peptoids	can	be	constructed	via	an	automated,	solid-phase	synthesis	[122].	The	submonomer	method	provides	a	robust	and	highly	efficient	platform	for	synthesis,	enabling	precise	control	over	sequence	functionality.	Synthesis	follows	a	carboxy	to	amino	direction,	in	which	each	cycle	of	monomer	addition	consists	of	a	two-step	process:	(1)	acylation	and	(2)	nucleophilic	substitution	(Figure	1.6.)	[121].	Functional	moieties	are	introduced	by	the	incorporation	of	commercially	available	primary	amines,	enabling	access	to	a	wide	variety	of	side	chain	chemistries	(>100	monomers)	[109].	High	monomer	coupling	efficiencies	(98%)	[123]	additionally	allow	for	the	precise	sequence-specific	synthesis	of	polymer	chains	surpassing	over	300	monomeric	subunits	in	length	[124].		
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	Figure	1.6.	Submononer	synthesis	on	Rink-amide	resin.	
Peptiods	allow	for	the	precise	spatial	positioning	of	diverse	chemical	functionalities,	enabling	the	design	of	novel	materials	with	distinct	chemical	properties.	Peptoids	are	of	great	interest	as	biomimetic	materials	for	therapeutic	applications	because	they	display	low	immunogenicity,	are	protease-resistant,	biocompatible,	and	soluble	in	water.	They	are	attractive	as	polymeric	materials	as	they	offer	a	remarkable	ease	of	assembly,	sequence	programmability,	and	relatively	low	costs.	In	addition,	they	enable	the	incorporation	of	a	variety	of	highly	customizable	side	chain	chemistries,	and	allow	for	the	precise	control	of	sequence	and	length	specificity,	as	well	as	the	formation	of	defined	three-dimensional	conformational	assemblies.	Lastly,	the	mimicry	of	the	natural	proteins	allows	for	the	study	of	fundamental	sequence,	structure,	and	function	relationships,	and	hence	potential	sighting	in	the	understanding	of	the	protein	structure-function	paradigm.	
2.	Research	Rationale	
While	knowledge	of	different	types	of	diseases	and	their	progression	has	grown	remarkably	in	the	last	decades,	the	economic	costs,	extensiveness	of	treatment,	and	mortality	associated	with	many	of	these	diseases	continue	to	in	large	be	hampered	by	our	ability	to	detect	when	therapeutic	treatments	present	their	greatest	potential—before	the	
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disease	is	widespread—the	incipient	stages	of	development.	Thus,	there	is	a	critical	need	to	develop	sensitive	assays	that	can	detect	molecular	changes	associated	with	the	onset	of	the	disease.	Enzyme-linked	immunosorbent	assay	(ELISA)	microarray	technology	offers	a	promising	mean	for	the	attainment	of	this	goal.	Surface	chemistries	and	immobilization	procedures	are	crucial	for	the	optimal	performance	of	microarray	platforms.	The	challenge	lies	in	the	immobilization	of	capture	molecules	of	diverse	structures	and	characteristics	onto	a	solid	support	in	a	manner	that	allows	for	strong	attachment,	but	also	retains	their	inherent	activity.	These	assays	need	to	display	high	reproducibility,	binding	capacities,	and	signal-to-noise	ratios.	Additionally,	the	high-throughput	nature	of	the	platform	requires	supports	to	be	robust	and	retain	high	levels	of	specificity	and	sensitivity	through	rigorous	processing	conditions	and	prolonged	storage	periods.	
	Figure	2.1.	Representative	schematic	for	the	increased	antibodies	binding.	
The	comprehensive	goal	of	this	project	is	to	develop	a	biocompatible	surface	coating	that	increases	the	available	surface	area. The	surface	area	difference	between	the	microsphere	
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coated	three-dimensional	surface	and	the	uncoated	two-dimensional	surface	given	the	average	microsphere	diameter	of	1.59	um	is	of	157%	assuming	that	antibody	immobilization	occurs	only	in	the	projected	top	half	of	each	microsphere.	We	hypothesize	that	the	proposed	peptoid-based	microsphere	coatings	will	enhance	the	binding	efficiency	of	capture	reagents,	increasing	the	dynamic	range	and	sensitivity	of	biosensor	technologies.	Peptoids	are	bio-inspired	sequence-specific	polymers	based	on	a	polyglycine	backbone	with	side	chains	appended	to	the	amide	groups.	Peptoids	are	attractive	as	biocompatible	materials	for	therapeutic	applications	because	of	their	relative	low	costs,	ease	of	synthesis,	highly	customizable	side-chain	chemistry,	biostability,	biocompatibility,	and	low	cytotoxicity.	The	Servoss	lab	has	demonstrated	that	helical	peptoids	with	partial	water	solubility	self-assemble	into	microspheres.		
The	hypothesis	will	be	confirmed	by	completing	the	following	aims:	
1. Compare	the	ELISA	microarray	performance	of	the	peptoid	microsphere-coated	
slides	with	commercially	available	slides.	We	hypothesize	that	the	increase	in	surface	area	provided	by	the	microsphere	coatings	will	enhance	the	dynamic	range	and	sensitivity	of	assays	performed	in	surfaces	providing	similar	chemistries	for	attachment.	The	proposed	peptoid-based	coating	will	be	assessed	in	reference	to	glass	and	poly-L-lysine	coated	surfaces	in	order	to	evaluate	non-covalent	and	covalent	immobilization	strategies.	The	binding	efficacy	of	the	peptoid	microsphere-coated	glass	substrates	will	be	analyzed	by	ELISA	microarray	with	known	antibody	assays.		
2. Investigate	the	factors	affecting	microsphere	morphology	following	deposition	on	
a	solid	surface.	We	hypothesize	that	the	ionic	properties	of	the	solvent,	including	ionic	
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strength,	pH,	and	Hofmeister	solubility,	play	a	crucial	role	in	determining	the	ultimate	stability	of	the	microspheres.	It	is	believed	that	pi-pi	stacking	of	the	chiral	aromatic	groups	along	with	hydrophobic	effects	lead	to	self-assembly	of	the	peptoids	into	microspheres.	Preliminary	robustness	studies	have	demonstrated	that	the	microsphere	coatings	are	able	to	withstand	all	processing	conditions	associated	with	ELISA	microarray,	but	prolonged	exposure	to	water	leads	to	degradation	of	the	peptoid	microspheres.	CD	will	be	used	in	order	to	determine	any	effect	on	helicity,	while	SEM	will	be	used	in	order	to	study	the	robustness	of	the	spheres	in	the	diverse	conditions.			
3. Investigate	the	effect	helicity	plays	on	microsphere	size	formations.	We	hypothesize	that	peptoid	sequences	exhibiting	stronger	helical	secondary	structure	will	form	smaller	microspheres	as	compared	to	those	peptoids	exhibiting	less	structured	helices.	Preliminary	findings	demonstrate	that	the	inclusion	of	positively	and	negatively	charged	groups	in	the	third	face	of	the	helix	formed	microspheres	nearly	10	times	smaller	than	those	obtained	with	the	sequence	being	currently	used.	It	is	believed	that	these	opposite	charges	interact	to	form	tighter	helices	which	result	in	the	smaller	supramolecular	assemblies	observed	[125].	CD	studies	will	be	performed	in	order	to	quantify	peptoid	helicity,	while	SEM	will	be	used	for	the	visual	assessment	of	microsphere	size.		
3.	Deposition	of	Uniform	Peptoid	Microspheres	Coatings	
3.1.	Materials	
Amine	sub-monomers:	4-methoxybenzylamine	and	(S)-methylbenzylamine	were	purchased	from	Acros	Organics	(Pittsburgh,	PA).	tert-butyl	N-(4-aminobutyl)carbamate	
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was	purchased	from	CNH	Technologies	Inc.	(Woburn,	MA).	MBHA	rink	amide	resin	was	purchased	from	NovaBiochem	(Gibbstown,	NJ).	Piperidine	was	purchased	from	Sigma-Aldrich	(St.	Louis,	MO).	Test	grade	silicon	wafers	were	purchased	from	University	Wafer	(South	Boston,	MA).	Poly-L-lysine	and	ultra	clean	glass	microarray	slides	were	purchased	from	Thermo	Scientific	(Pittsburgh,	PA).	Disuccinimidyl	suberate	(DSS)	and	bis[sulfosuccinimidyl]	suberate	(BS3)	were	purchased	from	Pierce	(Rockford,	IL,	USA).	Purified	antibodies	and	antigens	were	purchased	from	R&D	Systems	(Minneapolis,	MN,	USA).	Blocking	solution	containing	10	mg/ml	casein	in	phosphate-buffered	saline	(PBS)	was	purchased	from	Bio	Rad	Laboratories	(Hercules,	CA,	USA).	Tyramide	Signal	Amplification	(TSA)	system,	including	streptavidin-conjugated	horseradish	peroxidase,	amplification	diluent,	and	biotinyl	tyramide,	was	purchased	from	Perkin	Elmer	(Wellesley,	MA,	USA).	All	other	reagents	for	synthesis,	purification	and	sample	preparation	were	purchased	from	VWR	(Radnor,	PA).	All	chemicals	were	used	without	further	modification	unless	otherwise	specified.		
3.2.	Methods	
3.2.1	Peptoid	Synthesis	
Peptoids	were	synthesized	via	the	submonomer	solid-phase	method	on	rink	amide	resin	[122].	The	resin	was	initially	swelled	with	dimethylformamide	(DMF),	and	the	Fmoc	protecting	group	on	the	resin	was	removed	using	a	20%	solution	of	piperidine	in	DMF.	The	resin-bound	secondary	amine	was	acylated	with	0.4	M	bromoacetic	acid	(BAA)	in	DMF,	in	the	presence	of	N,N’-diisopropyl	carbodiimide	(DIC),	mixing	for	1	minute.	Amine	sub-
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monomers	were	incorporated	via	an	SN2	nucleophilic	substitution	reaction	with	0.5M	primary	amine	in	DMF,	mixing	for	2	minutes.	The	two-step	bromoacetylation	and	nucleophilic	substitution	cycle	were	repeated	until	all	desired	side	chains	has	been	incorporated	(Figure	3.1.).	Once	the	synthesis	was	complete,	the	peptoid	was	cleaved	from	the	resin	using	a	mixture	of	95%	trifluoroacetic	acid	(TFA),	2.5%	water,	and	2.5%	triisopropylsilane	(TIS),	mixing	for	5	minutes.	The	acid	was	removed	using	a	Heidolph	Laborota	4001	rotating	evaporator	(Elk	Grove	Village,	IL)	and	peptoids	were	diluted	to	a	concentration	of	~3	mg/mL	in	a	50:50	acetonitrile-water	solution.	
	Figure	3.1.	Peptoid	structure	for	the	P3	sequence.		
3.2.2	Purification	
Peptoids	were	purified	using	a	Waters	Delta	600	preparative	high-performance	liquid	chromatography	(HPLC)	instrument	(Milford,	MA)	with	a	Duragel	G	C18	150	×	20	mm	column	(Peeke	Scientific,	Novato,	CA)	using	a	linear	gradient	of	35-95%	solvent	B	(acetonitrile,	5%	water,	0.1%	TFA)	in	A	(water,	5%	acetonitrile,	0.1%	TFA),	over	60	minutes.		Peptoids	were	confirmed	to	be	>98%	pure	via	analytical	HPLC	(Waters	Alliance,	Milford,	MA)	with	a	Duragel	G	C18	150	×	2.1	mm	column	(Peeke	Scientific,	Novato,	CA)	
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using	a	linear	gradient	of	35	to	95%	solvent	D	(acetonitrile,	0.1%	TFA)	in	C	(water,	0.1%	TFA),	over	30	minutes.	Purified	peptoid	fractions	were	lyophilized	using	a	Labconco	lyophilizer	(Kansas	City,	MO)	and	stored	for	use	as	a	powder	at	-20	°C.	
3.2.3	Characterization	
Matrix	Assisted	Laser	Desorption/ionization	Time	of	Flight	(MALDI-TOF).	Proper	synthesis	was	confirmed	via	MALDI	(Bruker,	Billerica,	MA)	mass	spectrometry.		The	mass	of	the	purified	peptoid	samples	(Figure	3.2.)	matches	the	expected	theoretical	molecular	weight	(1917	Da).	
	Figure	3.2.	MALDI-TOF	spectrum	of	peptoid,	MW:	1917	Da.		
Circular	dichroism	(CD).	Secondary	structure	was	confirmed	via	CD	spectrometry	using	a	
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Jasco	J-715	instrument	(Easton,	MD)	at	room	temperature	with	a	scanning	speed	of	20	nm/min	and	a	path	length	of	0.1	mm.	The	spectra	(Figure	3.3.)	exhibits	the	characteristic	maxima	near	190	nm	and	two	minima	near	205	and	220	nm	commonly	associated	to	polyproline	type	I	helices	[121].	The	peptoid	was	dissolved	in	methanol	at	a	concentration	of	120	µM	because	protic	solvents	have	been	demonstrated	to	help	induce	helical	secondary	structure	in	peptoids.	Each	spectrum	was	the	average	of	twenty	accumulations.	
	Figure	3.3.	Circular	dichroism	spectra	of	peptoid	showing	a	poly-proline	type-1-like	helical	secondary	structure.	CD	spectra	were	taken	at	room	temperature	with	a	scanning	speed	of	20	nm/min	and	a	path	length	of	0.1	mm.	The	peptoid	was	dissolved	in	methanol	at	a	concentration	of	120	µM.	
3.2.4.	Microsphere	Formation	
Peptoid	microspheres	were	prepared	by	dissolving	the	peptoid	in	a	4:1	(v/v)	solution	of	various	organic	solvents/water	at	a	range	of	concentrations.	The	peptoid	solutions	were	deposited	onto	various	surfaces	of	approximately	1	cm	×	1	cm	using	a	pipette	under	a	
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variety	of	different	conditions.		
3.3.5	Morphology	Studies	
Scanning	electron	microscopy	(SEM).	Peptoid	microsphere	coating	morphologies	were	visually	assessed	at	the	Material	Characterization	Facility	using	a	Phillips	XL-30	environmental	SEM	(FEI,	Hillsboro,	OR)	in	order	to	determine	effect	of	a	number	of	optimization	conditions	on	both	the	ability	to	form	uniform	self-assembling	peptoid	microsphere	and	consequent	coatings	with	the	latter.		
3.3.	Peptoid	Microspheres	Coatings	
3.3.1.	Peptoid	Microspheres	
Previous	work	in	our	lab	has	shown	that	helical	peptoids	that	are	in	addition	partially	soluble	in	water	are	able	to	self-assemble	into	microspheres.	Helicity	in	the	structure	is	sterically	induced	with	the	inclusion	of	chiral	aromatic	side	chains	in	two	of	the	three	faces	of	the	helix	(Figure	3.1.).	Because	these	microspheres	(∼2	μm)	(Figure	3.4.)	are	orders	of	magnitude	larger	than	the	single	peptoid	helix	(∼24	Å),	we	have	proposed	that	the	stacking	of	the	chiral	aromatic	groups	allow	for	formation	of	larger	peptoid	groupings	that	coupled	to	hydrophobic	effects	self-assemble	into	microspheres	(Figure	3.5.)	[125].	Similar	types	of	supra-molecular	assemblies	have	been	observed	by	this	sort	of	aromatic	stacking	in	both	peptides	and	peptoids	[126]	[127]	[128]	[129]	[130].	
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	Figure	3.4.	SEM	image	of	peptoid	microsphere.		
	Figure	3.5.	Schematic	Representation	of	peptoid	microsphere	formation	[146].	
Past	work	in	our	lab	has	focused	in	the	analysis	of	various	parameters	(i.e.	partial	water	solubility,	helical	content,	charge	placement,	and	side	chain	bulk)	affecting	the	self-assembly	peptoids	microspheres	[125],	and	to	an	extent	even	the	reproducible	formation	of	these	microspheres	on	silica	surfaces	[131].	Focus	now	continues	on	to	the	controlled	deposition	of	robust	uniform	petoid	microsphere	coatings	on	glass	slides.	The	peptoid	sequence	that	has	been	selected	for	this	work	is	based	on	these	prior	studies.	SEM	studies	reveal	that	the	administration	technique	by	which	the	peptoid	solution	is	applied	to	a	surface	greatly	affected	the	uniformity	of	the	coating	and	suggest	that	the	horizontal	full	
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coverage,	as	compared	to	some	of	the	more	readily	utilized	high	throughput	alternatives,	such	as	dip	coating,	was	necessary	for	best	results.	In	order	to	ensure	reproducibility	of	results,	fixed	peptoid	volumes	were	administered	with	a	pipette,	covering	the	entire	surface	outlined	by	1	cm	×	1	cm	delimiting	wax	imprints.	It	has	been	shown	that	protic	solvents	aid	in	stabilizing	helical	secondary	structure	in	peptoids	through	hydrogen	bonding	[117]	[132]	[133]	[134].	Solvent	choice	was	investigated	with	the	use	of	three	different	protic	solvents	(i)	methanol,	(ii)	isopropanol,	and	(iii)	ethanol	(Figure	3.6.).	Peptoids	were	dissolved	in	4:1	organic	solvent/water	solution.	While	SEM	images	reveal	sphere-like	assemblies	for	all	solvents,	the	most	uniform	spheres	are	formed	with	the	use	of	ethanol	as	the	protic	solvent	choice.		
	Figure	3.6.	SEM	images	demonstrating	the	effect	of	different	protic	solvents	on	sphere	formation:	A)	methanol,	B)	isopropanol,	and	C)	ethanol.		
3.3.2.	Microsphere	Coatings	
The	effect	of	drying	conditions	was	similarly	investigated	by	varying	the	humidity	at	which	the	peptoid	solution	was	allowed	to	evaporate.	For	this	analysis,	the	peptoid	solutions	were	dried	at	(i)	high	humidity	(85%)	in	a	humid	chamber	(~120	minutes),	(ii)	open	air	(~30	minutes),	and	(iii)	vacuum	chamber	(~5	minutes).	Drying	conditions	greatly	affected	the	uniformity	of	the	spheres	and	coating	deposition	on	the	surface.	Whether	it	was	the	
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formation	of	sparse	clusters	of	non-uniform	globular	aggregates	at	vacuum	or	clumped	spheres	at	high-density	regions	towards	the	perimeter	and	center	of	the	coverage	area	at	a	high	humidity.	Open	air-drying,	although	with	its	own	detriments	(i.e.	still	perimetral	intensive	and	sparse	in	the	inner	region)	from	a	coverage	standpoint,	consistently	formed	the	most	uniform	microspheres	and	surface	coverage	(Figure	3.7.).		
	Figure	3.7.	SEM	images	demonstrating	the	microsphere	coatings	coverage	difference	at	the	perimeter	and	center.			
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	Figure	3.8.	Schematic	representation	of	the	coverage	uniformity	improvement	upon	addition	of	tween	surfactant.	
	Figure	3.9.	Microsphere	coating	coverage	with	optimized	conditions	at	3	different	magnifications.		Coating	morphology	is	directly	linked	to	the	mode	of	evaporation.	In	droplets,	it	is	known	that	at	atmospheric	pressure,	two	main	modes	of	evaporation	occur:	first,	droplets	flatten	with	a	constant	contact	area,	to	then	shrink	at	a	constant	contact	angle.	A	constant	contact	area	mode	of	evaporation	is	desired	in	order	to	obtain	uniform	coating	depositions.	In	addition,	perimetral	intensive	depositions	are	often	indicative	of	preferential	substrate	accumulations	at	the	air/liquid	interface.	The	addition	of	surfactants	can	be	used	to	preserve	a	constant	contact	area	mode	of	evaporation	by	decreasing	droplet	surface	tension,	lowering	the	contact	angle,	and	in	turn	improving	the	stability	of	the	droplet	by	reducing	the	pullback	forces	at	the	perimeter	during	evaporation.		In	addition,	surfactants	
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can	be	competitively	used	to	displace	substrates	at	the	air/liquid	interface,	and	thus	lessen	the	perimetral	deposition	on	the	surface	(Figure	3.8.).	Results	for	the	addition	of	Tween	surfactant	show	considerable	improvements	on	the	overall	uniformity	of	the	coating,	lessening	perimetral	microsphere	deposition	and	allowing	for	an	even	distribution	of	microspheres	throughout	the	entire	surface	(Figure	3.9.).	At	higher	concentrations	(>	0.1%)	Tween	addition	clumped	adjacent	microspheres	to	each	other,	and	when	added	to	the	solvent	prior	to	the	peptoid	affected	size	uniformity	in	microsphere	formation.	
In	order	to	increase	the	inner	region	coverage,	peptoid	concentrations	and	volumes	for	coverage	where	optimized.	It	was	possible	to	increase	peptoid	concentrations	from	3	mg/mL	to	5	mg/mL	to	increase	microsphere	coverage	density	without	disrupting	the	morphology	and	uniformity	of	either	the	spheres	or	coating	(Figure	3.10.).	Decreases	in	volume	of	peptoid	solution	added	greatly	affected	the	coverage	density	(Figure	3.11.),	while	increases	in	volume	only	further	increased	the	deposition	of	microspheres	towards	the	perimeter	with	minimal	inner	region	improvement.	
	Figure	3.10.	SEM	images	demonstrating	the	difference	in	microsphere	coverage	with	peptoid	concentration:	A)	3	mg/ml,	B)	4	mg/ml,	and	C)	5	mg/ml.		
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	Figure	3.11.	SEM	images	demonstrating	the	difference	in	microsphere	coverage	with	volumes:	A)	15	ul,	B)	30	ul,	and	C)	45	ul.		ImageJ	analysis	of	the	microsphere	coatings	demonstrate	83.5	±	3.4	%	surface	coverage	at	optimized	conditions.	Although	the	peptoid	microsph	ere	coating	has	similar	reactive	moieties	to	poly-L-lysine,	the	contact	angle	of	the	peptoid	microsphere	coating	is	considerably	more	hydrophobic	than	the	poly-L-lysine	slides,	53.2	±	3.9	degrees	versus	30.3	±	2.4	degrees.	In	general,	hydrophobic	surfaces	limited	solvent	spreading.	The	increased	roughness	of	the	peptoid	microsphere	coatings	as	compared	to	two	dimensional	surfaces	would	similarly	disrupt	solvent	spreading.		
4.	Detection	and	Validation	of	Cancer	Biomarkers		
4.1	Introduction	
Protein	microarrays	are	recognized	as	one	of	the	most	valuable	tools	in	proteomics.	In	protein	microarrays,	proteins	are	immobilized	on	a	solid	substrate	for	the	efficient	and	high-throughput	parallel	analysis	of	large	population	profiles.	The	technology	offers	a	wide	range	of	applications,	including	expression	profiling,	interaction	profiling,	and	functional	identification	[135].	Protein	concentration	profiles	may	depend	on	age,	physicochemical	characteristics	of	the	environment,	and	among	those	of	interest,	disease	state.	The	need	to	study	beyond	mRNA	profiling	arises	due	to	post	translational	modifications	and	general	
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protein	degradation	by	proteolysis.	Protein	screening	thus	offers	a	direct	way	to	phenotype	cells	and	diagnose	disease	state,	stage,	and	response	to	treatment	[135].	This	approach	has	been	successfully	explored	with	antibody	arrays,	where	microarray	protein	chips	based	on	immunological	antibody/antigen	interaction,	offer	the	necessary	high	specificity	and	sensitivity,	that	have	allowed	for	the	development	of	the	broad	applications	in	the	technology:	proteome	analysis,	disease	diagnostics,	identification	of	biomarkers,	and	pharmaceuticals	response	profiling	[136]	[137].	
Among	several	available	immunoassays,	ELISA	is	a	popular	because	of	its	high	specificity,	sensitivity,	and	high	throughput	[13].	In	ELISA,	capture	antibodies	are	first	immobilized	onto	a	solid	support.	Those	capture	antibodies	then	bind	to	specific	antigen.	The	chip	is	then	incubated	with	a	detection	antibody	that	binds	to	the	same	antigen	as	the	capture	antibody,	but	does	so	at	a	different	site.	Finally,	the	detection	antibodies	are	tagged	with	a	fluorescent	dye,	before	the	slide	is	scanned	for	a	fluorescent	signal	with	a	laser	scanner.	The	intensity	of	the	fluorescence	signal	is	directly	related	to	the	concentration	of	the	substrate,	and	thus	allow	for	the	quantitative	application	of	results.		
4.2	Materials	
Poly-L-lysine	and	ultra	clean	glass	microarray	slides	were	purchased	from	Thermo	Scientific	(Pittsburgh,	PA).	Disuccinimidyl	suberate	(DSS)	was	purchased	from	Pierce	(Rockford,	IL,	USA).	Purified	antibodies	and	antigens	were	purchased	from	R&D	Systems	(Minneapolis,	MN,	USA).	Additional	antibodies	and	glycans	were	provided	by	our	collaborators	at	Detroit	R&D.	Blocking	solution	containing	10	mg/ml	casein	in	phosphate-buffered	saline,	pH	7.2	(PBS)	was	purchased	from	Bio	Rad	Laboratories	(Hercules,	CA,	
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USA).	Tyramide	Signal	Amplification	(TSA)	system,	including	streptavidin-conjugated	horseradish	peroxidase,	amplification	diluent,	and	biotinyl	tyramide,	was	purchased	from	Perkin	Elmer	(Wellesley,	MA,	USA).	Alexa647-conjugated	streptavidin	was	purchased	from	Invitrogen	Life	Technologies	(Gaithersburg,	MD).	All	other	reagents	were	purchased	from	VWR	(Radnor,	PA).	All	chemicals	were	used	without	further	modifications	unless	otherwise	specified.		
4.3.	Methods	
4.3.1	Microarray	Printing	
ELISA	microarray	spotting	was	performed	at	room	temperature	and	60%	relative	humidity	as	previously	described	[138].	A	GeSiM	NanoPlotter	2.1	(Quantum	Analytics,	Foster	City,	CA,	USA)	non-contact	microarray	printer	with	humidity	control	was	utilized	to	spot	the	proteins.	In	some	cases,	proteins	were	covalently	boud	t	the	slides	with	a	0.3	mg/ml	solution	of	the	homo-bifunctional	cross-linker	DSS	mathanol	for	20	minutes.	Prior	to	spotting,	the	slides	were	rinsed	in	nanopure	water	and	dried	in	a	centrifuge.	Capture	antibodies	were	suspended	in	PBS	to	a	concentration	of	0.5-1.0	mg/ml	and	~400	picoliters	per	spot	were	printed	at	various	different	layouts.	The	antibodies	were	allowed	to	dry	for	an	additional	hour	at	60%	relative	humidity.	The	slides	were	blocked	with	10	mg/ml	casein	in	PBS,	rinsed	in	nanopure	water	and	dried	in	a	centrifuge.	Upon	completion,	the	slides	were	either	stored	under	vacuum	for	future	use	at	-20	°C	or	shipped	to	our	collaborators.		
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4.3.2	ELISA	Microarray		
ELISA	Microarray	was	performed	as	previously	described	[138],	with	all	incubation	steps	performed	at	room	temperature,	in	a	closed	humid	chamber	with	gentle	mixing	on	an	orbital	shaker	(Belly	Dancer,	Stovall	Life	Science,	Greensboro,	NC).	A	two-step	wash	procedure	between	processing	steps	was	performed	by	submerging	the	slides	twice	into	PBS	containing	0.05%	Tween-20	(PBS-T).	The	slides	were	incubated	with	different	antigen	standards	in	1	mg/ml	casein	in	PBS	overnight.	Standard	curves	were	created	using	a	five-fold	dilution	series	of	the	antigen	mix	along	with	an	antigen-free	blank	for	8	total	dilutions.	Following	a	wash	cycle,	the	slides	were	incubated	with	biotinylated	detection	antibody	at	25	ng/ml	in	1	mg/ml	casein	in	PBS.	The	signal	was	amplified	using	the	TSA	system	following	manufacturer	instructions,	and	incubated	with	1	μg/ml	Alexa647-conjugated	streptavidin	in	PBS-T.	Prior	to	scanning,	the	slides	were	rinsed	twice	in	PBS-T	and	in	deionized.	A	GenePix	Autoloader	4200AL	(Molecular	Devices,	CA)	laser	scanner	was	used	to	image	the	Alexa	647	fluorescence	signal	on	the	slides.	The	spot	fluorescence	intensity	from	the	scanned	slide	images	was	quantified	using	GenePix	Pro	3.0	software.	Standard	curves	were	created	using	ProMAT,	a	software	program	specifically	developed	for	the	analysis	of	ELISA	microarray	data	[139].		
4.4.	ELISA	Microarray	Marker	Assays	
4.4.1.	Antibody	Assays	
Initial	research	was	conducted	for	the	development	of	standard	curves	on	26	different	ELISA	microarray	antibody	assays.	Large	studies	insert	greater	indices	of	variation	that	are	
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reflected	on	the	quality	of	standard	curves	that	can	be	developed.	For	this	reason,	significant	work	was	conducted	on	further	optimizing	standard	curves	of	all	antibodies.	In	order	to	do	so,	special	focus	was	placed	on	the	development	of	a	new	antigen	mix	for	the	development	of	the	standard	curves.	The	optimized	antigen	concentration	can	be	seen	in	Table	1.	EGF,	GFP,	and	PSA	antigens	were	excluded	from	the	antigen	mix	and	prepared	as	separate	independent	stock	solutions	from	which	to	be	added	fresh	for	each	experiment.	Additionally,	we	developed	a	homemade	biotinyltryramide	and	amplification	diluent.	These	solutions	were	compared	to	the	TSA	amplification	kit	solutions,	obtaining	very	favorable	results	with	comparable	quality.	In	order	to	prevent	any	undesired	interactions	that	might	compromise	assay	specificity	and	sensitivity,	cross-activity	studies	were	first	performed	on	all	antibodies.	Cross-reactivity	studies	involve	a	series	careful	evaluations	[66].	In	short,	individual	antigen	and	detection	antibody	pairs	are	first	tested	on	arrays	containing	all	capture	antibodies.	Undesired	interactions	would	be	detected	upon	evaluation	of	signal	intensities,	no	cross-reactivity	of	either	the	antigen	or	the	detection	antibody	with	any	capture	antibody	was	detected.	Nonspecific	antigen	contamination	is	then	similarly	assessed,	however	this	time	with	all	antigens	present.	A	final	round	of	screenings	is	conducted.	These	screens	consist	in	preparing	separate	antigen	mixes	by	removing	one	of	the	antigens	from	the	mix,	and	screening	each	mix	independently	using	a	mixture	with	all	detection	antibodies,	and	then	doing	the	opposite,	preparing	separate	detection	antibody	mixes,	and	screening	each	mix	independently	using	all	mixture	with	all	antigens.	Cross-reactivity	was	detected	between	the	TGFalpha	and	FGFb	antibodies.	FGFb	was	removed	from	future	studies	for	this	reason.	
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4.4.2.	Sample	Screenings	
Serum	sample	from	cancer	patients	were	screened	to	validate	the	potential	markers.	For	the	initial	9-sample	analysis,	microarray	slides	with	a	10x12	array	layout	containing	all	26	different	antibodies	in	quadruplicate	were	first	spotted	(Table	4.1.).	For	analysis,	three	different	dilutions	of	each	serum	sample	in	triplicate	were	utilized.	Antigen	concentrations	can	vary	by	as	much	as	3	orders	of	magnitude	[66];	for	this	reason	samples	are	commonly	screened	at	three	different	dilutions	(10-fold,	100-fold,	and	1000-fold).	The	samples	were,	in	addition,	arranged	at	random	in	order	to	prevent	result	bias	associated	with	the	placement	and	processing	of	samples.	Using	this	ELISA	platform,	we	were	able	to	detect	13	different	antigens	in	the	patient	samples	(CD14,	EGF,	EGFR,	Eselectin,	GDF-15,	HBEGF,	Her2,	ICAM,	IL18,	MMP1,	PDGF-AA,	PSA,	and	RANTES),	as	the	other	were	below	detection	limits	(Amr,	FGFb,	HGF,	IGF,	IL1alpha,	MMP2,	MMP9,	TGFalpha,	TGFb,	TNFalpha,	uPAR,	and	VEGF).		
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Table	4.1.	Summary	of	the	results	detailing	the	maximal	concentration	for	all	antigens.	
Antigen	 Max.	Conc.	 Antigen	 Max.	Conc.	
Amr	 2000	 IL18	 1000	
CD14	 5000	 IL1alpha	 500	
EGF	 500	 MMP1	 5000	
EGFR	 2500	 MMP2	 5000	
Eselectin	 2500	 MMP9	 2000	
FGFb	 5000	 PDGF-AA	 1000	
GDF-15	 250	 PSA	 5000	
GFP	 100	 RANTES	 500	
HBEGF	 500	 TGFalpha	 500	
Her2	 5000	 TGF-b	 5000	
HGF	 1000	 TNF-alpha	 500	
ICAM	 10000	 uPAR	 5000	
IGF	 2000	 VEGF	 750		The	next	major	undertaking	was	proceeding	with	an	82-sample	analysis	that	expanded	on	the	previous	study.	For	this	analysis,	only	two	different	dilutions	(10	and	100-fold)	of	each	serum	sample	in	triplicates	were	used.	The	analysis	was	conducted	in	3	replicate	batches	in	random	ordering	as	before.	Each	batch	was	conducted	using	17	slides,	with	3	standard	curves	present	for	each.	The	data	was	calibrated	to	the	GFP	spot	using	ProMAT	in	an	effort	to	account	for	any	spot,	slide,	location,	and/or	batch	variations.	All	standard	curves	and	predicted	concentrations	along	with	data	detailing	information	for	each	particular	sample	as	it	relates	to	each	antibody	and	batch,	as	well	as	a	comparison	for	averaged	block	
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intensities	for	A647	and	GFP	on	uncalibrated	data	to	allow	for	an	analysis	on	block	to	block	variations	were	sent	to	Detroit	R&D.	In	general,	results	for	the	analysis	demonstrated	similar	trends,	with	CD14,	EGF,	EGFR,	GDF-15,	ICAM,	PDGF-AA,	and	RANTES	displaying	best	results.		
4.4.3.	Glycan	Prints.		
Throughout	this	time,	microarray	slides	most	often	with	the	10x12	array	layout	containing	the	25	different	antibodies	in	quadruplicate	were	constantly	spotted	and	shipped	to	our	collaborators	for	further	processing.	Once	the	sample	analysis	concluded,	work	focused	on	the	printing	of	different	markers	of	interest,	in	particular	glycans.	Glycan	microarray	slides	with	a	6x6	array	layout	containing	all	5	different	glycans	were	spotted	at	a	concentration	of	0.5	mg/mL	in	quadruplicate	for	each	block.	In	order	to	proceed	with	the	spotting	of	the	glycans,	the	poly-l-lysine	slides	were	first	activated	with	the	DSS.		Although	full	analysis	was	not	performed	on	the	slides,	as	they	were	shipped	immediately	upon	printing	to	Detroit	R&D,	the	quality	of	the	spotting	was	confirmed	with	the	scanner	using	the	red	reflect	setting	on	the	microarray	scanner.	Another	frequent	glycan	print	involved	a	12x12	array	containing	25	different	glycans	at	a	concentration	of	0.5	mg/mL	and	6	different	antibody	standards	at	concentrations	of	of	1000,	100,	10,	1	ug/mL	in	0.5	ug/mL	BSA	in	PBS.	The	print	was	conducted	in	quadruplicate	for	each	block	for	a	total	of	16	blocks	per	slide	in	DSS	activated	poly-l-lysine	slides.	Similarly,	larger	38x8	arrays	containing	74	different	antibodies	at	two	different	concentrations	(0.5	and	0.05mg/ml)	in	quadruplicate	for	each	block	for	a	total	of	4	blocks	per	slide	were	spotted	and	sent	to	Detroit	R&D	for	analysis.		
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5.	Identification	of	Tear	Cancer	Biomarkers	
5.1	Introduction	
Clinical	applications	remain	limited	by	the	need	for	more	sensitive	and	reliable	methodologies	for	detection	[140].	Tears	fluids	offer	non-invasive	insight	into	a	complex	biological	environment	providing	valuable	information	that	might	help	reveal	associations	between	proteins	and	disease	states.	Proteomic	technologies	have	currently	identified	close	to	500	different	tear	proteins	[141]	[142].	In	this	study,	we	develop	a	ELISA	microarray	platform	for	the	identification	of	tear	proteins	as	potential	biomarkers	for	breast	cancer.		
5.2	Materials	
Poly-L-lysine	and	ultra	clean	glass	microarray	slides	were	purchased	from	Thermo	Scientific	(Pittsburgh,	PA).	Disuccinimidyl	suberate	(DSS)	was	purchased	from	Pierce	(Rockford,	IL,	USA).	Purified	antibodies	and	antigens	were	purchased	from	R&D	Systems	(Minneapolis,	MN,	USA).	Proteins	were	provided	by	our	collaborators	at	Ascendant	Dx.	Blocking	solution	containing	10	mg/ml	casein	in	phosphate-buffered	saline,	pH	7.2	(PBS)	was	purchased	from	Bio	Rad	Laboratories	(Hercules,	CA,	USA).	Tyramide	Signal	Amplification	(TSA)	system,	including	streptavidin-conjugated	horseradish	peroxidase,	amplification	diluent,	and	biotinyl	tyramide,	was	purchased	from	Perkin	Elmer	(Wellesley,	MA,	USA).	Alexa647-conjugated	streptavidin	was	purchased	from	Invitrogen	Life	Technologies	(Gaithersburg,	MD).	All	other	reagents	were	purchased	from	VWR	(Radnor,	PA).	All	chemicals	were	used	without	further	modifications	unless	otherwise	specified.		
40		
5.3.	Methods	
5.3.1	Microarray	Printing	
ELISA	microarray	spotting	was	performed	at	room	temperature	and	60%	relative	humidity	as	previously	described	[138].	A	GeSiM	NanoPlotter	2.1	(Quantum	Analytics,	Foster	City,	CA,	USA)	non-contact	microarray	printer	with	humidity	control	was	utilized	to	spot	the	proteins.	In	some	cases,	proteins	were	covalently	boud	t	the	slides	with	a	0.3	mg/ml	solution	of	the	homo-bifunctional	cross-linker	DSS	mathanol	for	20	minutes.	Prior	to	spotting,	the	slides	were	rinsed	in	nanopure	water	and	dried	in	a	centrifuge.	Capture	antibodies	were	suspended	in	PBS	to	a	concentration	of	0.5-1.0	mg/ml	and	~400	picoliters	per	spot	were	printed	at	various	different	layouts.	The	antibodies	were	allowed	to	dry	for	an	additional	hour	at	60%	relative	humidity.	The	slides	were	blocked	with	10	mg/ml	casein	in	PBS,	rinsed	in	nanopure	water	and	dried	in	a	centrifuge.	Upon	completion,	the	slides	were	either	stored	under	vacuum	for	future	use	at	-20	°C	or	shipped	to	our	collaborators.		
5.3.2	ELISA	Microarray		
ELISA	Microarray	was	performed	as	previously	described	[138],	with	all	incubation	steps	performed	at	room	temperature,	in	a	closed	humid	chamber	with	gentle	mixing	on	an	orbital	shaker	(Belly	Dancer,	Stovall	Life	Science,	Greensboro,	NC).	A	two-step	wash	procedure	between	processing	steps	was	performed	by	submerging	the	slides	twice	into	PBS	containing	0.05%	Tween-20	(PBS-T).	The	slides	were	incubated	with	different	antigen	standards	in	1	mg/ml	casein	in	PBS	overnight.	Standard	curves	were	created	using	a	five-fold	dilution	series	of	the	antigen	mix	along	with	an	antigen-free	blank	for	8	total	dilutions.	
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Following	a	wash	cycle,	the	slides	were	incubated	with	biotinylated	detection	antibody	at	25	ng/ml	in	1	mg/ml	casein	in	PBS.	The	signal	was	amplified	using	the	TSA	system	following	manufacturer	instructions,	and	incubated	with	1	μg/ml	Alexa647-conjugated	streptavidin	in	PBS-T.	Prior	to	scanning,	the	slides	were	rinsed	twice	in	PBS-T	and	in	deionized.	A	GenePix	Autoloader	4200AL	(Molecular	Devices,	CA)	laser	scanner	was	used	to	image	the	Alexa	647	fluorescence	signal	on	the	slides.	The	spot	fluorescence	intensity	from	the	scanned	slide	images	was	quantified	using	GenePix	Pro	3.0	software.	Standard	curves	were	created	using	ProMAT,	a	software	program	specifically	developed	for	the	analysis	of	ELISA	microarray	data	[139].		
5.4.	ELISA	Microarray	Platform	for	the	Identification	of	Cancer	Biomarkers	in	Tear	
Samples	
Tear	samples	were	collected	from	inside	the	lower	eyelid	using	Schirmer	strips,	and	subsequently	reconstituted	in	PBS	for	future	use.	Reverse-phase	high-pressure	liquid	chromatograph	was	used	to	fractionate	tear	proteins	for	identification.	A	linear	gradient	of	20%-30%	solvent	B	(acetonitrile,	5%	water,	0.1%	TFA)	in	A	(water,	5%	acetonitrile,	0.1%	TFA)	over	the	first	10	minutes,	followed	by	30%-70%	solvent	B	in	A	gradient	over	the	next	60	minutes,	and	a	70%-90%	solvent	B	in	A	gradient	over	the	last	10	minutes	was	used	for	a	total	of	80	minutes	[143].	Collected	proteins	were	analyzed	via	electrospray	ionization	mass	spectrometry	(ESI-MS).	
Preliminary	studies	with	our	collaborators	at	Ascendant	Dx	helped	identify	7	main	tears	proteins	of	interest	as	potential	biomarkers	for	breast	cancer.	In	order	to	detect	and	validate	these	proteins	as	potential	biomarkers,	a	sandwich	ELISA	microarray	based	
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platform	was	developed.	Microarray	ELISA	allows	for	the	parallel	screening	of	multiple	proteins	(refer	to	section	1.2.2	for	additional	details).	However,	in	multiplexed	studies	there	exists	the	potential	for	proteins	from	different	assays	to	interfere	with	each	other.	This	can	happen	via	direct	interactions	between	capture	and	detection	antibodies,	as	well	as	antibodies	nonspecifically	binding	to	another	antigen	or	antigens	present.	In	order	to	prevent	any	undesired	interactions	that	might	compromise	assay	specificity	and	sensitivity,	cross-activity	studies	were	first	performed	on	all	7	antibodies.	No	cross-reactivity	was	detected	by	the	screenings.	Standard	curves	were	developed	in	order	to	ensure	accurate	quantification	of	tear	samples	(Figure	5.1.).	Of	the	7	proteins	analyzed,	4	proteins	were	successfully	detected	in	the	human	tear	samples.		
	Figure	5.1.	Standard	curves	for	representative	tear	protein	assay.	Data	is	representative	of	the	other	antibody	assays.				
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6.	Biocompatible	Interfaces	for	Neural	Differentiation	
6.1.	Introduction	
The	use	of	stem	cell	regenerative	medicine	depends	on	understanding	the	complex,	dynamic	interactions	that	occur	in	the	extracellular	matrix	(ECM).	While	differences	in	the	mechanical	and	chemical	interfacial	properties	of	this	environment	have	shown	promising	effects	on	diverse	cellular	functions,	the	underlying	role	matrix	interfacial	properties	play	on	stem	cell	differentiation	is	yet	to	be	fully	understood.	Efforts	to	mimic	the	extracellular	matrix	via	surface	modifications	are	an	attractive	approach	to	understand	the	mechanisms	by	which	stem	cells	respond	to	inherent	interfacial	cues	that	affect	cellular	behavior.	Herein,	we	report	the	development	of	synthetic	biocompatible	interfaces	that	allow	for	the	tuning	of	chemical	and	mechanical	properties	of	the	matrix.		
The	devastating	effects	that	are	commonly	associated	with	traumatic	brain	injuries	and	degenerative	diseases	stem	from	limited	regenerative	capabilities	of	the	central	nervous	system	(CNS).	Among	current	tissue	engineering	strategies,	stem	cell-based	regenerative	approaches	have	demonstrated	promising	results	[144].	Neural	stem	cells	(NSCs)	are	a	self-renewing	and	multipotent	cells	that	can	differentiate	into	neurons	and	glia,	composed	mainly	of,	astrocytes	and	oligodendrocytes	[145].	The	differentiation	of	NSCs	into	neurons	is	crucial	for	regenerative	purposes.	Stem	cell	differentiation	is	regulated	by	a	combination	of	complex	intrinsic	and	extrinsic	interactions.	Intrinsic	factors	are	dependent	on	cell	expression,	while	extrinsic	factors	are	dependent	on	environment	cues	[146].	For	this	reason,	a	number	of	different	scaffolds	have	been	studied	in	an	attempt	to	develop	a	cellular	environment	that	allows	for	the	selective	differentiation	of	NSCs	[147]	[148]	[149]	
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[150]	[151]	[152].	
Engineering	this	artificial	extracellular	matrices	(aECM)	allow	to	elucidate	the	proud	influence	a	cell’s	environment	has	on	its	progression.		These	studies,	offer	valuable	mechanistic	insights	into	the	complex	interactions	that	occur	in	the	cellular	environment.	A	scaffold’s	stiffness,	for	example,	elicits	different	responses.	Neural	stem	cells	reach	maximal	differentiation	at	a	stiffness	similar	to	that	of	the	brain	(500	Pascal)	[153].	In	general,	softer	substrates	tend	to	preferentially	differentiate	into	neurons,	while	stiffer	substrates	tend	to	preferentially	differentiate	into	glial	cells	[151].	Studies	also	demonstrate	that	topographical	cues	in	the	nanometer	range	elicit	different	responses,	be	that	in	roughness	[154]	or	geometry	[155].	Cell	behavior	can	also	be	influence	by	the	presence	of	different	growth	factors	[156].	Three-dimensional	scaffolds	appear	to	similarly	better	mimic	the	physiological	environment	that	two-dimensional	variants	[157]	[158].	
6.2.	Peptoid	Microspheres	Interfaces	
Initial	research	was	conducted	in	order	to	assess	the	viability	of	using	peptoid	based	microspheres	in	the	development	of	an	artificial	extracellular	matrix	(aECM)	that	can	be	tailored	to	promote	the	differentiation	of	stem	cells	into	neurons.	Peptoid	microspheres	were	prepared	under	sterile	conditions.	All	laboratory	equipment	and	materials	were	sterilized	using	a	70%	ethanol	solution	and/or	autoclaved.	While	the	microsphere	coated	slides	cannot	be	sterilized	via	the	same	ethanol	based	sterilization	technique	as	they	are	formed	in	a	very	similar	solvents	composition,	and	thus	dissolve	the	peptoid	coatings	from	the	surface,	different	sterilization	techniques,	such	as	UV-sterilization	and	ethylene	oxide	gas	sterilization,	have	proven	to	be	viable	alternatives.	Peptoid	microspheres	were	
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prepared	by	dissolving	the	peptoid	in	4:1	(or	80%)	ethanol	to	water	solution	at	a	concentration	of	3	mg/ml.	The	addition	of	0.01%	Tween-20	surfactant	onto	the	peptoid	solution	improves	the	overall	uniformity	of	the	coatings,	allowing	for	an	even	distribution	of	microspheres	throughout	the	entire	surface.	The	peptoid	solution	was	applied	to	the	back	(un-etched)	face	of	the	coverslips	and	allowed	to	dry	for	30	minutes	in	a	contained	environment	under	controlled	conditions	(i.e.,	25	°C	and	60%	humidity).	Three	different	coating	densities	were	prepared	by	varying	the	amount	of	peptoid	solution	added	to	each	coverslip.	This	approach	has	given	us	in	the	past	control	over	the	coating	coverage.	A	1X	concentration	corresponds	to	30	uL	of	the	peptoid	solution	being	added	onto	the	surface.	A	2X	concentration	corresponds	to	a	second	30	uL	addition	of	the	peptoid	solution	being	added	onto	the	existing	1X	microsphere	coverage,	in	essence	doubling	the	concentration.	Similarly,	a	3X	concentration	corresponds	to	a	third	30	uL	addition	of	the	peptoid	solution	being	added	onto	the	existing	2X	microsphere	coverage,	tripling	concentration.	The	coating	morphologies	were	visually	assessed	using	a	3D	Laser	Scanning	Microscope	(Figure	6.1.).	SEM	images	require	gold	sputtering,	and	thus,	are	not	a	viable	imaging	technique	to	assess	the	morphology	of	the	coatings.	The	coverslips	were	prepared	for	shipped	with	the	help	of	Josh	Goss	from	Dr.	Zou’s	research	group	at	the	University	of	Arkansas	following	the	exact	specification	used	in	the	past.	In	short,	the	peptoid-coated	12mm	cover	slips	were	mounted	onto	the	back	of	35mm	petri	dishes	drilled	with	9mm	holes,	sterilized	previously	via	70%	ethanol	and	plasma	treatment,	using	PDMS.	The	peptoid	cmicropher	coated	coverslips	were	sent	to	Dr.	Michael	Borrelli’s	research	group	for	neuronal	studies	at	the	University	of	Arkansas	for	Medical	Sciences	as	part	of	the	EPSCoR	project.	
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	Figure	6.1.	3D	laser	scanning	microscope	images	of	the	peptoid-based	microsphere	coated	cover	slips	for	all	three	concentrations:	1X,	2X,	and	3X.	
6.3.	Nano-Onion	Interfaces		
In	the	field	of	tissue	engineering,	graphene-based	nano-materials,	as	are	nano-onions,	have	gained	interest	as	biocompatible	scaffold	due	to	their	unique	physical,	mechanical,	and	chemical	properties	[159].	Carbon	nano-onions	are	multi-shell	fullerenes	that	resemble	the	structure	of	onion,	hence	the	origin	of	their	name	[160].	Graphene-based	nano-materials	have	been	demonstrated	to	induce	stem	cell	differentiation	in	neural	lineages	[161].	They	are	attractive	for	neural	tissue	regeneration	because	they	can	incorporate	extraordinary	topographical,	thermal,	and	electrical	properties	to	scaffolds	[162].	They	have	been	demonstrated	to	be	biocompatible	and	of	low	cytotoxicity	materials	[163].	In	addition,	they	can	be	chemically	modified	to	enable	the	incorporation	of	diverse	functional	features	[164].	
Nano-onion	nano-patterned	coverslips	were	developed	in	order	to	asses	where	their	surface	incorporation	can	regulate	NSC	differentiation.	Nano-onion	patterned	slides	were	similarly	prepared	under	sterile	conditions.	Morphology	of	the	patterns	was	evaluated	via	SEM.	The	non-contact	nanoplotter	was	used	to	spot	different	patterns	across	the	glass	coverslips.	The	nano-onions	dispersions	were	prepared	by	dissolving	the	nano-onions	nanoparticles	at	a	1	mg/mL	concentration	in	a	optimized	solvent,	which	consists	of	a	1%	
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BSA	w/w,	0.05%	Tween-20	surfactant	v/v,	and	5%	glycerol	v/v	nano-pure	water	solution.	The	nano-onions	were	initially	were	thoroughly	mixed	using	a	vortexer	and	then	further	dispersed	using	a	probe	sonicator,	and	printed	immediately	using	the	non-contact	nano-plotter	Once	the	printing	was	complete,	the	coverslips	were	allowed	to	dry	at	standard	conditions	(25	C	and	~50%	humidity)	for	24	hours.	Results	with	the	optimized	conditions	considerably	improved	nano-onion	solvent	dispersion	and	deposition	uniformity	(Figure	6.2.).	The	addition	of	glycerol	was	particularly	beneficial	when	patterning	lines	over	the	surface.	However,	overall	spot	patterns	produced	the	most	uniformly	reproducible	patterns.	In	addition,	they	greatly	decrease	spotting	times	considerably.	Higher	nano-onion	concentrations	made	solvent	pick	up	difficult	for	the	nano-plotter.	Based	on	previous	work	a	higher	glycerol	content	would	similarly	difficult	spotting	for	the	nano-plotter	as	the	solution	turns	too	viscous.	The	addition	of	0.05%	Tween-20	surfactant	onto	the	nano-onion	solution	improves	both	nano-onion	dispersion	and	the	uniformity	of	the	patterns,	allowing	for	an	even	distribution	of	nano-onion	patterned	solutions	on	the	surface.	Higher	surfactant	spread	too	much	and	affect	reproducibility,	in	particular	when	patterning	lines	instead	of	spots.	Spot	patterns	with	5	mm	margins	on	22	x	22	mm	on	glass	coverslips	for	a	patterned	coverage	of	12	x	12	mm	were	printed	for	Dr.	Robert	Griffin’s	research	group	for	neuronal	studies	at	the	University	of	Arkansas	for	Medical	Sciences	as	part	of	the	EPSCoR	project.	
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	Figure	6.2.	SEM	images	demonstrating	the	effect	of	optimized	solvent	on	nano-onion	depositions	at	different	magnifications	A)	line	pattern	at	1%	BSA	in	water,	and	B)	spot	pattern	at	1%	BSA,	0.05%	Tween-20	surfactant	in	water.	
7.	Peptoid	Microsphere	Coatings	to	Increase	the	Binding	Efficiency	in	Sandwich	
ELISA	Microarrays	
7.1.	Introduction		
Over	the	last	several	decades	there	has	been	an	enormous	effort	to	develop	sensitive,	disease-specific	assays	to	assist	in	therapeutic	decisions	[1].	Early	disease	detection	decreases	economic	costs,	improves	treatment	options,	and	reduces	mortality	[6].	Biomarker-based	technologies,	including	ELISA	microarray	and	bead-based	immunoassay,	offer	promising	platforms	for	sensitive	and	specific	disease	detection	[4].	Enzyme-linked	immunosorbent	assay	(ELISA)	microarray	technology	has	emerged	as	a	strong	platform	for	the	analysis	of	biomarkers	[45]	due	to	its	ability	to	quantify	low-abundance	proteins	in	
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complex	biological	fluids	over	large	concentration	ranges	[65].	The	unmatched	sensitivity	and	specificity	is	associated	primarily	with	the	use	of	matched	high-affinity	antibody	pairs	to	target	a	single	antigen.	The	miniature	scale	of	the	platform	allows	for	cost-effective	and	efficient	parallel	screening	of	small	sample	volumes	in	a	high-throughput	manner	[45].		
One	of	the	main	challenges	in	the	development	of	ELISA	microarray	is	the	immobilization	of	antibodies	onto	a	solid	support	in	a	manner	that	maintains	their	innate	binding	properties	[24].	The	surface	chemistry	of	the	solid	support	and	the	immobilization	procedure	are	crucial	for	optimal	performance	of	microarray	platforms,	as	is	evident	by	the	large	number	of	slide	surfaces	commercially	available	[77]	[81]	[82]	[83]	[84]	[85]	[86].	Surfaces	for	ELISA	microarray	need	to	provide	strong	attachment	of	the	immobilized	antibodies	while	retaining	binding	activity,	high	binding	capacities,	high	signal-to-noise	ratios,	and	high	reproducibility	across	all	blocks,	slides,	and	experiments.	Additionally,	the	high-throughput	nature	of	the	platform	requires	supports	to	be	robust	and	retain	high	levels	of	specificity	and	sensitivity	through	rigorous	processing	conditions	and	prolonged	storage	periods.	
Although	there	are	a	number	of	immobilization	strategies	and	solid	supports	available,	microarray	surfaces	can	be	broadly	categorized	as	(1)	two-dimensional	surfaces	and	(2)	three-dimensional	surfaces.	While	two-dimensional	surfaces	allow	for	the	direct	attachment	of	proteins	to	the	surface	(aldehyde	[89]	[92],	aminosilane	[77]	[93]	[94],	epoxysilane	[93]	[94],	mercaptosilane	[94],	polystyrene	[77],	and	poly-L-lysine	coated	slides	[65]),	three-dimensional	surfaces	retain	proteins	within	a	matrix	(polyacrylamide	[89]	[95],	agarose	[90]	and	nitrocellulose	gels	[96]	[97]	[98]	[99]	[100]	[101],	as	well	as	
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poly(vinylidene	fluoride)	(PVDF)	membranes	[102]	[103]).	In	addition,	there	exist	more	specialized	chemistries	that	are	more	difficult	to	categorize	as	they	combine	characteristics	of	the	two;	while	they	do	not	provide	a	three-dimensional	structure	within	which	proteins	are	retained,	they	incorporate	some	supramolecular	assemblies	[24].	Some	examples	include	avidin	[105],	streptavidin	[84],	nickel	[92],	dendrimer	[106]	[107],	or	polyethylene	glycol	(PEG)	slides	[108].	These	surfaces	immobilize	proteins	through	the	covalent	attachment	of	epoxy	or	specialized	affinity	groups.		
Numerous	variables	affect	antibody	microarrays	including	surface	modifications,	cross-linking	strategies,	spotting	buffer	compositions,	blocking	reagents,	antibody	concentrations,	and	storage	conditions	[94]	[77]	[165]	[166]	[78].	Among	two-dimensional	surfaces,	poly-L-lysine	and	cross-linked	silane	slides	perform	best,	displaying	good	sensitivity	and	signal-to-noise	ratios	[94].	Nitrocellulose	surfaces,	on	the	other	hand,	exhibited	low	signal-to-noise	ratios	with	high	signal	intensities	as	well	as	high	background	signals	[94].	Similar	studies,	comparing	limits	of	detection,	coefficients	of	variation,	and	storage	characteristics	for	different	commercially	available	slide	chemistries	determined	that	in	terms	of	overall	array	performance	poly-L-lysine	and	aldehyde	slides	displayed	the	best	signal	uniformity	and	signal-to-noise	ratios	[77].	Aldehyde	silane,	poly-L-lysine,	or	aminosilane	slides	were	also	observed	to	produce	superior	result	in	an	independent	study	[83]	.	A	comprehensive	study	evaluating	17	commercially	available	microarray	surfaces	proposes	a	rigorous	and	quantitative	system	for	comparing	different	surfaces	based	on	spot	morphology,	background	noise,	limit	of	detection,	and	reproducibility	with	23	antibody	assays	[78].	
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Microarray	surfaces	need	to	provide	high	surface	areas	for	binding	that	enable	high	signal-to-noise	ratio	and	flexible	immobilization	chemistries.	Oligomeric	N-substituted	glycines	(peptoids)	are	promising	as	biosensor	interfaces	due	to	their	low	immunogenicity,	ease	of	synthesis,	highly	customizable	side	chain	chemistries,	and	the	ability	to	form	supramolecular	structures	that	can	increase	surface	area	[109].	Peptoids	are	bioinspired,	peptidomimetic	polymers	with	a	backbone	structure	closely	resembling	that	of	peptides,	but	with	the	side	chains	appended	to	the	amide	groups	rather	than	the	α-carbons.	This	structural	modification	prevents	proteolytic	degradation,	making	peptoids	attractive	as	biocompatible	materials.	However,	this	modification	also	removes	the	presence	of	backbone	amide	hydrogens,	which	are	critical	for	the	formation	of	the	hydrogen	bond	linkages	that	stabilize	beta	sheets	and	helices	in	peptides.	Despite	these	limitations,	secondary	structures	including	turns,	loops,	and	helices,	as	well	as	supramolecular	assemblies	such	as	superhelices	[167],	nanosheets	[168],	nanotubes	[169]	and	microspheres	[125]	can	be	induced	in	peptoids	upon	the	addition	of	specific	side	chains.	Peptoid	helices	have	been	demonstrated	to	form	polyproline	type-I-like	helices,	similar	to	those	of	proteins,	with	a	periodicity	of	three	monomers	per	turn	and	pitch	of	approximately	6	Å	with	as	few	as	five	monomer	units	[120].	
In	this	study,	we	report	the	development	of	peptoid	microsphere-coated	glass	substrates	for	use	in	sandwich	ELISA	microarray.	The	morphology	and	uniformity	of	the	coatings	was	evaluated	by	SEM	and	the	coating	efficacy	was	analyzed	by	ELISA	microarray	with	known	antibody	assays.	The	peptoid	microsphere-coated	surfaces	were	found	to	exhibit	higher	signal	intensity	and	dynamic	range	as	compared	to	commercially	available	microarray	surfaces.	
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7.2.	Materials	and	Methods	
7.2.1.	Materials	
4-methoxybenzylamine	and	(S)-methylbenzylamine	were	purchased	from	Acros	Organics	(Pittsburgh,	PA).	tert-butyl	N-(4-aminobutyl)carbamate	was	purchased	from	CNH	Technologies	Inc.	(Woburn,	MA).	MBHA	rink	amide	resin	was	purchased	from	NovaBiochem	(Gibbstown,	NJ).	Piperidine	was	purchased	from	Sigma-Aldrich	(St.	Louis,	MO).	Test	grade	silicon	wafers	were	purchased	from	University	Wafer	(South	Boston,	MA).	Poly-L-lysine	and	ultra	clean	glass	microarray	slides	were	purchased	from	Thermo	Scientific	(Pittsburgh,	PA).	Disuccinimidyl	suberate	(DSS)	and	bis[sulfosuccinimidyl]	suberate	(BS3)	were	purchased	from	Pierce	(Rockford,	IL,	USA).	Purified	antibodies	and	antigens	were	purchased	from	R&D	Systems	(Minneapolis,	MN,	USA).	Blocking	solution	containing	10	mg/ml	casein	in	phosphate-buffered	saline,	pH	7.2	(PBS)	was	purchased	from	Bio	Rad	Laboratories	(Hercules,	CA,	USA).	Tyramide	Signal	Amplification	(TSA)	system,	including	streptavidin-conjugated	horseradish	peroxidase,	amplification	diluent,	and	biotinyl	tyramide,	was	purchased	from	Perkin	Elmer	(Wellesley,	MA,	USA).	Alexa647-conjugated	streptavidin	was	purchased	from	Invitrogen	Life	Technologies	(Gaithersburg,	MD).	All	other	reagents	were	purchased	from	VWR	(Radnor,	PA).	All	chemicals	were	used	without	further	modifications	unless	otherwise	specified.		
7.2.2.	Peptoid	Synthesis	
Peptoids	were	synthesized	via	the	submonomer	solid-phase	method	on	rink	amide	resin,	as	previously	described	[170].	Briefly,	the	resin	was	swelled	with	dimethylformamide	(DMF)	
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and	the	Fmoc	protecting	group	on	the	resin	was	removed	using	a	20%	solution	of	piperidine	in	DMF.	The	resin-bound	secondary	amine	was	acylated	with	0.4	M	bromoacetic	acid	(BAA)	in	DMF	in	the	presence	of	N,N’-diisopropyl	carbodiimide	(DIC).	Amine	submonomers	were	incorporated	via	an	SN2	nucleophilic	substitution	reaction	with	primary	amine	in	DMF.	The	two-step	bromoacetylation	and	nucleophilic	substitution	cycle	was	repeated	until	all	desired	side	chains	were	incorporated.	The	peptoid	was	cleaved	from	the	resin	using	a	mixture	of	95%	trifluoroacetic	acid	(TFA),	2.5%	water,	and	2.5%	triisopropylsilane	and	the	acid	was	removed	using	a	Heidolph	Laborota	4001	rotating	evaporator	(Elk	Grove	Village,	IL).	The	peptoid	was	lyophilized	to	a	powder	using	a	Labconco	lyophilizer	(Kansas	City,	MO)	and	diluted	to	a	concentration	of	~3	mg/ml	in	a	50:50	acetonitrile-water	solution.		
7.2.3.	Peptoid	Purification	
Peptoids	were	purified	using	a	Waters	Delta	600	preparative	high-performance	liquid	chromatography	(HPLC)	instrument	(Milford,	MA)	with	a	Duragel	G	C18	150	×	20	mm	column	(Peeke	Scientific,	Novato,	CA)	and	a	linear	gradient	of	35-95%	solvent	B	(acetonitrile,	5%	water,	0.1%	TFA)	in	A	(water,	5%	acetonitrile,	0.1%	TFA),	over	60	minutes.		Peptoids	were	confirmed	to	be	>98%	pure	via	analytical	HPLC	(Waters	Alliance,	Milford,	MA)	with	a	Duragel	G	C18	150	×	2.1	mm	column	(Peeke	Scientific)	using	a	linear	gradient	of	35	to	95%	solvent	D	(acetonitrile,	0.1%	TFA)	in	C	(water,	0.1%	TFA),	over	30	minutes.	Purified	peptoid	fractions	were	lyophilized	and	stored	as	a	powder	at	-20	°C.	
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7.2.4.	Peptoid	Characterization	
Synthesis	of	the	desired	peptoid	sequence	was	confirmed	via	matrix	assisted	laser	desorption/ionization	time	of	flight	(MALDI-TOF;	Bruker,	Billerica,	MA)	mass	spectrometry.	Secondary	structure	was	confirmed	via	CD	spectrometry	using	a	Jasco	J-715	instrument	(Easton,	MD)	at	room	temperature	with	a	scanning	speed	of	20	nm/min	and	a	path	length	of	0.1	mm.	The	peptoid	was	dissolved	in	methanol	at	a	concentration	of	120	µM	because	protic	solvents	have	been	demonstrated	to	help	induce	helical	secondary	structure	in	peptoids.	Each	spectrum	was	the	average	of	twenty	accumulations.	
7.2.5.	Peptoid	Microsphere	Coatings	
Peptoid	microspheres	were	prepared	by	dissolving	the	peptoid	in	a	4:1	(v/v)	ethanol/water	solution	at	a	concentration	of	5	mg/ml,	as	previously	described	[125].	Glass	slides	(Erie	Scientific,	Portsmouth,	NH)	were	outlined	with	an	8	x	2	array	pattern	using	a	Barnstead	Thermolyne	microarray	slide	imprinter	(Dubuque,	IA)	to	create	a	hydrophobic	barrier	for	processing	16	wells	per	slide.	The	peptoid	solution	was	applied	to	the	glass	surfaces	and	allowed	to	dry	at	room	temperature	and	60%	relative	humidity.	Coating	morphologies	were	visually	assessed	using	a	Phillips	XL-30	scanning	electron	microscope	(SEM)	(FEI,	Hillsboro,	OR).	
7.2.6.	Microarray	Printing	
ELISA	microarray	printing	was	performed	at	room	temperature	and	60%	relative	humidity	as	previously	described	[138].	A	GeSiM	NanoPlotter	2.1	(Quantum	Analytics,	Foster	City,	CA,	USA)	non-contact	microarray	printer	with	humidity	control	was	used	to	spot	the	
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antibodies.	Prior	to	spotting,	the	microsphere	coated	surfaces,	and	in	some	cases	the	poly-L-lyisne	slides,	were	treated	with	a	0.3	mg/ml	solution	of	the	homo-bifunctional	cross-linker	BS3	in	PBS	for	20	minutes	to	create	a	reactive	site	for	covalent	attachment	via	the	amine	groups.	After	incubation,	the	slides	were	rinsed	in	nanopure	water	and	dried	in	a	centrifuge.	Capture	antibodies	were	suspended	in	PBS	to	a	concentration	of	0.8	mg/ml	and	~400	picoliters	per	spot	were	printed	500	um	apart	in	quintuplicate	on	each	array.	Upon	completion,	the	antibodies	were	allowed	to	dry	for	an	additional	hour	at	60%	relative	humidity.	The	slides	were	blocked	with	10	mg/ml	casein	in	PBS	and	processed	immediately.		
7.2.7.	ELISA	Microarray		
ELISA	Microarray	was	performed	as	previously	described	[138],	with	all	incubation	steps	performed	in	a	closed	humid	chamber	with	gentle	mixing	on	an	orbital	shaker	(Belly	Dancer,	Stovall	Life	Science,	Greensboro,	NC),	in	the	dark,	at	room	temperature.	A	two-step	wash	procedure	between	processing	steps	was	performed	by	submerging	the	slides	twice	into	PBS	containing	0.05%	Tween-20	(PBS-T).	The	slides	were	incubated	with	a	mixture	of	antigen	standards	in	1	mg/ml	casein	in	PBS	overnight.	Standard	curves	were	created	using	a	three-fold	dilution	series	of	the	antigen	mix	along	with	an	antigen-free	blank	for	twelve	total	dilutions.	Following	a	wash	cycle,	the	slides	were	incubated	with	biotinylated	detection	antibody	at	25	ng/ml	in	1	mg/ml	casein	in	PBS.	The	signal	was	amplified	using	the	TSA	system	following	manufacturer	instructions,	and	incubated	with	1	μg/ml	Alexa647-conjugated	streptavidin	in	PBS-T.	Lastly,	the	slides	were	rinsed	twice	in	PBS-T	and	lastly	in	deionized	prior	to	scanning.	
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A	GenePix	Autoloader	4200AL	(Molecular	Devices,	CA)	laser	scanner	was	used	to	image	the	Alexa	647	fluorescence	signal	on	the	slides.	The	spot	fluorescence	intensity	from	the	scanned	slide	images	was	quantified	using	GenePix	Pro	3.0	software.	Standard	curves	were	created	using	ProMAT,	a	software	program	specifically	developed	for	the	analysis	of	ELISA	microarray	data	based	on	a	four-parameter	logistic	curves	model	[139].	The	values	for	the	lower	limits	of	detection	are	calculated	as	the	mean	concentration	plus	three	standard	deviations	of	the	log-transformed	spot	intensity	for	the	antigen-free	blank.	In	order	to	provide	a	value	that	is	representative	of	all	assays	for	comparisons,	a	relative	limit	of	detection	value	was	calculated	using	the	median	value	for	all	assay	replicates	on	each	surface.	Results	shown,	unless	noted	otherwise,	encompass	three	replicate	experiments	performed	using	slides	that	were	coated,	printed,	and	processed	on	independent	occasions.		Statistical	significance	was	assessed	using	a	t-test	with	a	95%	confidence	intervals	where	probabilities	of	p	<	0.05	were	considered	statistically	significant.		
7.3.	Results	and	Discussion	
7.3.1.	Peptoid	Sequence	Rationale	
Our	lab	has	previously	shown	that	partially	water-soluble,	helical	peptoids	self-assemble	into	microspheres	[125].	The	peptoid	sequence,	referred	to	as	P3	(Figure	7.1.),	includes	chiral,	aromatic	side	chains	on	two	faces	of	the	helix	to	induce	the	formation	of	helical	secondary	structure	[131].		The	third	face	of	the	helix,	which	offers	considerable	flexibility	of	design,	contains	methoxy	and	amine	groups	to	increase	water	solubility.	The	amine	groups	also	enables	covalent	linkage	to	and	electrostatic	interactions	with	the	slide	surface.	The	secondary	structure	of	P3	was	determined	by	circular	dichroism,	which	confirms	poly-
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proline	type-I-like	secondary	structure	(Figure	S7.1.	in	Supplemental	Information)	[121].		
	Figure	7.1.	Peptoid	structure	for	the	P3	sequence.
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7.3.2.	Coating	Characterization	
The	formation	of	uniform	peptoid	microsphere	coatings	is	essential	to	reduce	variability	in	ELISA	microarray	assays.	Coating	morphology	is	directly	linked	to	evaporation	rate,	requiring	careful	monitoring	of	drying	conditions	to	ensure	uniform	sphere	distribution	and	reproducible	coatings.	One	issue	observed	in	the	formation	of	peptoid	coatings	is	perimetral	intensive	deposition,	often	referred	to	as	the	“coffee	ring	effect”,	in	which	denser	coverage	is	observed	at	the	perimeter	of	the	coatings	as	compared	to	the	center.	Previous	studies	have	shown	that	this	effect	is	reduced	when	samples	are	evaporated	at	a	constant	contact	area,	which	can	be	achieved	by	including	surfactant	in	the	microsphere	solution	[171].		The	addition	of	Tween-20	to	the	peptoid	microsphere	solution	results	in	improved	coating	uniformity,	lessening	perimetral	microsphere	deposition	and	allowing	for	an	even	distribution	of	microspheres	on	the	surface	(Figure	7.2.).	At	concentrations	>0.1%,	Tween-20	disrupts	microspheres	formation	and	alters	microspheres	size	distribution	(Figure	S7.2.	in	Supplemental	Information).	
Microarray	results	of	the	microsphere	coated	slides	demonstrated	very	faint	fluorescent	signals,	indicative	of	a	weak	surface	attachment	of	the	antibodies.	To	enhance	immobilization,	the	peptoid	microsphere	coated	surfaces	were	covalently	attached.	BS3	treatment	greatly	reduced	the	antibody	loss	at	the	surface	due	to	the	wash	steps	necessary	for	processing	the	slides.	Consistent	with	findings	elsewhere	[78],	studies	for	all	assays	on	poly-L-lysine	surfaces	demonstrate	no	significant	difference	when	assessing	antibodies	immobilized	on	non-covalent	surfaces	as	compared	to	those	attached	covalently	(Figure	S7.3.	in	Supplemental	Information).	This	supports	the	notion	that	the	increase	in	intensities	
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associated	to	the	microsphere	coatings	occurs	as	a	result	of	the	increase	in	surface	area	available	for	binding.	It	is	also	important	to	note	that	although	higher	backgrounds	are	observed	with	the	coatings,	such	background	fluorescence	was	observed	independent	of	covalent	treatment.		
	Figure	7.2.	Peptoid	microsphere	coated	glass	surfaces.	Peptoids	were	dissolved	in	a	4:1	(v/v)	ethanol/water	solution	at	a	concentration	of	5	mg/ml.	The	peptoid	solution	was	applied	to	the	glass	surfaces	and	allowed	to	dry	at	room	temperature	and	60%	relative	humidity.	
7.3.3.	Coating	Efficacy	for	ELISA	Microarray	
The	efficacy	of	the	peptoid	microsphere	coatings	was	evaluated	by	ELISA	microarray	with	four	antibody	assays,	previously	shown	to	have	good	assay	sensitivity	and	specificity	and	low	cross-reactivity	in	multiplexed	ELISA	microarray	(Table	1)	[117].	The	performance	of	the	surfaces	was	evaluated	based	on	spot	morphology,	signal	to	noise	ratio,	limit	of	detection,	and	concentration	dynamic	range.	Signal	intensities	were	evaluated	by	comparing	single	concentration	assays	on	peptoid-based	microsphere	coated	blocks	with	‘uncoated’	poly-L-lysine	surfaces.	Single	point	antigen	concentrations	correspond	to	the	third	dilution	of	the	three-fold	standard	curve	dilution	series	(i.e.	approximately	11%	of	the	maximal	concentration),	previously	shown	to	provide	a	strong	signal	intensity	near	
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saturation	and	in	the	upper	usable	range	of	the	standard	curve	[66].		
Spot	morphology	is	dependent	on	the	characteristics	of	the	surface.	The	increased	topographical	complexity	of	three-dimensional	surfaces	presents	its	challenges.	Although	the	spot	morphology	on	peptoid	microspheres	is	not	as	crisp	as	those	on	the	two-dimensional	poly-L-lysine	surfaces,	they	are	greatly	improved	over	other	three-dimensional	surfaces	[78].	As	is	the	case	with	other	three-dimensional	slide	surfaces,	the	peptoid	microsphere	coated	surface	exhibits	higher	backgrounds	of	fluorescence	as	compared	to	the	two-dimensional	surface	(Figure	7.3.B).	Despite	the	increased	background	signal,	the	signal-to-noise	ratio	for	the	peptoid	microsphere	coating	is	the	same	as	or	higher	than	the	poly-L-lysine	coating.		
Table	7.1.	Summary	of	the	results	detailing	the	maximal	concentration	of	antigens,	lower,	upper	bound,	dynamic	range	concentrations,	and	single	point	signal	intensities	(11%	of	the	maximal	concentration)	for	the	‘uncoated’	poly-L-lysine	surfaces	and	peptoid-based	microsphere	coated	surfaces	antigens	for	all	5	different	assays:	CD14	(cluster	of	differentiation	14),	GFP	(green	fluorescent	protein),	HGF	(hepatocyte	growth	factor),	and	RANTES	(regulated	on	activation	normal	T	cell	expressed	and	secreted).	Statistical	significance	was	assessed	using	a	t-test	with	a	95%	confidence	intervals	where	*p<0.05,	**p<0.01,	and	***p<0.001	for	assays	on	uncoated	vs.	coated	surfaces.		
Assay	 Max	Conc.	 Limit	of	Detection	 Dynamic	Range	 Signal/Noise	Ratio		 	 Uncoated	 Coated	 Uncoated	 Coated	 Uncoated	 Coated	CD14	**	 2500	 1.9	 2.0	 527.8	 530.2	 21.4	 21.3	GFP	***	 500	 0.2	 0.7	 80.0	 97.0	 17.8	 30.5	HGF	***	 1000	 0.3	 2.7	 135.3	 492.8	 20.7	 30.6	RANTES	***	 500	 0.4	 0.3	 64.6	 264.2	 15.8	 16.8		
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	Figure	7.3.	A)	Images	of	fluorescence	for	GFP	and	HGF	with	BS3	treatment	on	a)	peptoid	microsphere	coated	glass	surfaces,	b)	uncoated	poly-L-lysine	surfaces.	B)	Comparison	of	background	fluorescence	for	the	peptoid	microsphere	coated	glass	surfaces	and	‘uncoated’	poly-L-lysine	surfaces.	Columns	and	cross-bars	represent	the	means	and	standard	deviations,	respectively,	of	the	median	spot	backgrounds	on	‘uncoated’	poly-L-lysine	slides	and	‘coated’	peptoid	microsphere	surfaces	across	three	replicate	experiments.	C)	Comparison	of	single	point	signal	intensities	(11%	of	the	maximal	concentration)	for	all	antibody	assays	(CD14,	GFP,	HGF,	and	RANTES)	on	peptoid	microsphere	coated	glass	surfaces	with	BS3	treatment	and	uncoated	poly-L-lysine	surfaces.	Columns	and	cross-bars	represent	the	means	and	standard	deviations,	respectively,	of	the	signal	intensities	on	‘uncoated’	poly-L-lysine	slides	and	‘coated’	peptoid	microsphere	surfaces	printed	and	processed	at	the	same	time,	and	representative	of	additional	replicate	studies.		The	performance	of	the	peptoid	microsphere	coatings	was	compared	to	commercial	poly-L-lysine	surfaces,	which	are	widely	used	for	antibody	assays	[126]	and	provide	a	similar	chemistry	for	antibody	attachment	as	the	peptoid	microsphere	coatings.		As	compared	to	poly-L-lysine	slides,	peptoid	microsphere	coated	surfaces	consistently	displayed	stronger	
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signal	intensities,	averaging	a	two-fold	increase,	under	identical	processing	conditions	(Figure	7.3.C	and	Table	7.1.).	This	observation	is	clear	for	all	assays	and	consistent	whether	the	comparisons	are	based	on	a	single	concentration	point	(Figure	7.3.C)	or	over	the	full	standard	curve	(Figure	7.4.).		
	 	
Figure	7.4.	Standard	curves	for	HGF	on	‘uncoated’	poly-L-lysine	slides	and	‘coated’	peptoid	microsphere	surfaces	on	a	log	10	vs	log	3	plot.	Results	are	representative	of	the	trends	observed	across	all	antibody	assays	(see	Figure	S7.4.	in	Supplemental	Information).	Data	points	and	cross-bars	represent	the	means	and	standard	deviations,	respectively.	The	standard	curves	encompass	data	from	all	three	replicate	experiments	performed	using	slides	that	were	coated,	printed,	and	processed	on	independent	occasions.		The	limit	of	detection	is	a	direct	assessment	of	assay	sensitivity,	in	other	words	the	lowest	concentration	that	can	be	reliably	detected.	Evaluation	of	surface	performance	is	based	on	previously	published	methods,	where	relative	limit	of	detection	below	2	is	‘superior’,	between	2	and	4	is	‘normal,	and	above	4	is	‘poor’	[78].	Despite	the	larger	standard	deviations	at	low	antigen	concentration	for	the	peptoid	microsphere	coatings	they	are	rated	in	the	superior	category	with	a	score	of	0.9	±	0.5	as	compared	to	a	score	of	0.8	±	0.3	
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for	poly-L-lysine	slides	in	our	study.	These	values	are	comparable	to	published	values	for	commercially	available	slides	including	poly-L-lysine	(0.7	±	0.1),	aminosilane	(1.3	±	0.6),	aldehyde	silane	(1.1	±	0.4),	epoxysilane	(1.2	±	0.6),	Slide	E	(0.8	±	0.4),	and	Full	Moon	(1	±	0.7)	[78].		
As	hypothesized,	the	peptoid	microsphere	coatings	have	increased	dynamic	range	as	compared	to	poly-L-lysine	slides	(Table	1).	ProMAT	outlines	the	useful	range	of	the	standard	curves	by	defining	the	lower	limits	of	detection	and	upper	concentration	bound.	As	the	standard	curve	for	HGF	in	Figure	7.4.	demonstrates,	and	Table	1	details	for	all	assays,	there	exists	an	increase	in	the	concentration	dynamic	ranges	observed	for	the	peptoid	microsphere	coated	surfaces	as	compared	to	‘uncoated’	poly-L-lysine	surfaces.	Though	the	extent	of	the	increase	varies	(2.4	for	CD14,	17	for	GFP,	357.5	for	HGF,	and	199.6	pg/ml	for	RANTES),	this	increase	is	consistently	observed	for	most	assays.		
Although	the	performances	of	the	assays	are	directly	associated	to	the	characteristics	of	the	surfaces,	it	is	important	to	recognize	the	importance	of	the	protocols	by	which	the	assays	are	spotted,	blocked,	and	processed	for	fluorescent	scanning.	It	is	quite	possible	that	the	performance	of	the	microsphere	coated	surfaces	hold	ample	room	for	improvement.	For	instance,	adjustments	to	the	spotting	protocols,	in	particular	the	spotting	buffer,	offer	significant	potential.	Many	of	the	more	complex	three-dimensional	surfaces	often	require	specialized	spotting	buffers.	We	found	that	the	addition	of	5%	glycerol	(Figure	S7.5.	in	Supplementary	Information)	can	improve	spot	morphology,	one	of	the	main	detriments	the	microsphere	coatings	suffer.	Increases	in	the	density	of	spotting	buffers	limits	spot	spreading,	decreasing	spot	diameters,	and	thus	improving	the	overall	spot	morphology.	
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While	more	densely	printed	arrays	yield	high	signal	intensities,	they	also	complicate	surface	evaluations	as	it	inserts	an	additional	variable	to	the	comparisons.	Results	on	these	coatings	are	promising	because	they	validate	peptoid	coatings	as	viable	material	for	biosensor	applications,	as	well	as	demonstrate	an	increase	in	the	dynamic	range	associated	to	the	increased	binding	affinity	these	surfaces	offer.	
7.4.	Conclusion	
High-throughput	demands	in	protein	detection	(including	ELISA	microarray	and	biosensors)	require	the	selection	and	development	of	optimized	support	surfaces	that	allow	for	more	generally	applicable	and	direct	immobilization	procedures.	While	high	binding	affinities	are	imperative	to	prevent	antibody	loss	and	ensure	robust	attachment,	the	challenge	lies	in	designing	a	microarray	support	that	accommodates	proteins	of	varying	characteristics	and	provides	a	non-denaturing	environment	to	preserve	the	active	form	of	the	protein.	We	have	evaluated	the	use	of	peptoid	microsphere	coatings	as	a	novel	surface	for	the	improvement	of	sandwich	ELISA	microarrays.	This	peptoid-based,	three-dimensional	coating	offers	a	customizable,	water	insoluble,	biocompatible	interface	that	increases	the	surface	area	available	for	protein	binding.	The	efficacy	of	the	coating	was	assessed	in	terms	of	its	overall	array	performance	as	compared	to	commercially	available	poly-L-lysine	coated	surfaces	[81]	[94].	The	coatings	allowed	for	strong	covalent	antibody	attachment	and	performed	well	in	terms	of	limits	of	detection.	The	increase	in	surface	area	enables	higher	protein	binding	capacities	as	compared	to	two-dimensional	poly-L-lysine	surfaces.	Although	the	peptoid	microsphere	coatings	displayed	higher	background	fluorescence	and	coefficients	of	variation,	higher	signal-to-noise	ratios	were	observed	
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compared	to	poly-L-lysine	surfaces.		
The	peptoid	microsphere	coatings	provide	an	exciting	new	interface	for	a	wide	range	of	biosensor	applications.	Results	suggest	that	existing	biosensor	protocols	and	procedures	(printing,	blocking,	processing,	and	storage)	can	be	readily	applied	to	peptoid	microsphere	coatings	and	that	the	coatings	outperform	state-of-the	art	surfaces	such	as	poly-L-lysine.	The	robust	peptoid	microsphere	coated	surface	provides	a	versatile	platform	that	can	be	easily	customizable.	It	offers	the	benefits	that	come	with	an	increased	surface	area	for	binding,	while	at	the	same	time	allow	for	use	of	familiar	chemistries	that	are	established	for	both	protein	microarray	and	biosensor	applications.		
	
	
	
66		
7.6.	Supplemental	Information	
	
	
	
	
	
	
	Figure	S7.1.	Circular	dichroism	spectra	of	peptoid	showing	a	poly-proline	type-1-like	helical	secondary	structure.	CD	spectra	were	taken	at	room	temperature	with	a	scanning	speed	of	20	nm/min	and	a	path	length	of	0.1	mm.	The	peptoid	was	dissolved	in	methanol	at	a	concentration	of	120	µM.	
	Figure	S7.2.	Effects	of	Tween-20	on	microsphere	coatings:	A)	0.001%,	B)	0.01%,	C)	0.1%,	and	D)	1%	by	volume.	
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	Figure	S7.3.	Comparison	of	signal	intensities	across	all	antibody	assays	(CD14,	GFP,	HGF,	ICAM,	and	Rantes)	on	uncoated	poly-L-lysine	surfaces	based	on	non-covalent	attachments	and	covalent	attachments	via	BS3	treatment.	
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	Figure	S7.4.	Standard	curves	for	all	antibody	assays	on	‘uncoated’	poly-L-lysine	slides	and	the	peptoid-based	microspheres	coated	glass	surfaces	on	a	log	10	vs	log	3	plot.		
	Figure	S7.5.	Improvement	on	spot	morphology	upon	the	addition	of	5%	glycerol	(bottom)	to	the	GFP	1mg/ml	casein	in	PBS	spotting	buffer.		
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8.	Peptoid	Microsphere	Coatings:	The	Effects	of	Helicity,	pH,	and	Ionic	Strength	
8.1.	Introduction		
Natural	polymers	have	inspired	the	development	of	synthetic	materials	that	mimic	the	fundamental	molecular	features	that	allow	for	the	diverse	array	of	functions	found	in	nature	[109].	Proteins	have	a	myriad	of	unique	functional	properties,	providing	for	example,	binding	and	catalytic	sites	that	together	enable	molecular	recognition.	However,	as	biomaterials	peptides	present	a	major	drawback	due	to	proteolytic	degradation	and	as	a	result	are	limited	in	their	potential	for	biomedical	and	therapeutic	applications	[110].	Efforts	to	overcome	these	limitations	have	led	to	the	design	and	development	of	innovative	peptidomimetic	oligomers	[111]	[112]	[113]	[114]	[115]	[116].	These	synthetic	polymer	analogs	predominately	exploit	structural	similarities	in	order	to	allow	for	the	mimicry	of	bioactive	functionalities.	Bioactive	roles	however,	are	often	determined	by	the	unique	ability	of	peptides	to	self-assemble	into	complex,	sequence-specific	three-dimensional	secondary	structures	[117].	Specific	peptidomimetic	oligomers,	commonly	referred	to	as	foldamers	[118],	display	well-defined	secondary	structures,	are	therefore	of	great	interest	for	use	in	biomaterials.	
Peptoids	are	a	form	of	bio-mimetic	synthetic	polymers	that	closely	resemble	peptides,	but	have	the	side	chains	attached	to	the	backbone	amide	nitrogen	rather	than	to	the	α-carbon	as	in	peptides.	Like	peptides,	peptoids	can	be	constructed	via	solid-phase	synthesis	[122]	following	a	submonomer	method	that	provides	a	robust	and	highly	efficient	platform	for	synthesis,	enabling	precise	sequence	control.	Synthesis	follows	a	carboxy	to	amino	direction,	in	which	each	monomer	cycle	includes	(1)	acylation	and	(2)	nucleophilic	
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substitution	[121].	Functional	moieties	are	introduced	by	the	incorporation	of	commercially	available	primary	amines,	enabling	access	to	more	than	300	side	chain	chemistries	[109].	Monomer	coupling	efficiencies	of	>98%	[123]	allow	for	the	precise	sequence-specific	synthesis	of	polymer	chains	surpassing	over	300	monomeric	subunits	in	length	[124].		
The	seemingly	minor	modification	to	the	backbone	has	important	implications	to	peptoid	structure	and	Function.	Peptoids	are	not	susceptible	to	proteolytic	degradation,	making	them	a	promising	alternative	to	peptides	for	therapeutic	applications	where	proteolysis	is	of	major	concern.	However,	the	backbone	modification	also	prevents	backbone	hydrogen	bonding,	which,	although	critical	for	the	formation	of	secondary	structure	in	peptides	can	be	overcome	by	including	specific	side	chains	to	form	secondary	structures	such	as	turns	[172]	[173],	loops	[174],	and	helices	[175]	[123]	[120]	[132]	[133]	that	in	turn	allow	for	the	formation	of	supramolecular	assemblies	[167]	[149]	[176]	[127]	[168]	[125].	Stable	helices	can	be	formed	by	peptoids	as	short	as	five	monomer	units	with	circular	dichroism	(CD)	spectra	that	strongly	resemble	those	of	protein	α-helices	[117].	NMR	studies	show	that	peptoids	have	a	helical	structure	similar	to	polyproline	type-I	helices	in	proteins,	with	a	periodicity	of	three	residues	per	turn	and	a	pitch	of	~6	Å	[120].	
Past	work	in	the	Servoss	lab	has	focused	on	the	effect	of	various	parameters	on	the	self-assembly	of	peptoids	into	microspheres	including	water	solubility,	helical	content,	charge	placement,	and	side	chain	bulk	[125].	It	was	demonstrated	that	helicity	and	partial	water	solubility	are	crucial	for	microsphere	formation.	Furthermore,	peptoid	sequences	with	alternating	opposite	charges	on	one	face	of	the	helix	produce	smaller	microspheres	(~0.3	
71		
μm)	as	compared	to	those	with	only	positive	charges	(~1.5	μm).		It	is	believed	that	the	opposite	charges	interact	to	form	tighter	helices,	which	result	in	the	smaller	supramolecular	assemblies	observed	[125].	The	microspheres	formed	are	orders	of	magnitude	larger	than	a	single	peptoid	helix	(∼24	Å),	supporting	the	theory	that	larger	peptoid	groupings	are	formed	by	stacking	of	the	chiral	aromatic	groups	[125].	Aromatic	stacking	has	been	observed	in	similar	types	of	supramolecular	assemblies	in	both	peptides	and	peptoids	[126]	[127]	[128]	[129]	[130].	Further	work	investigated	the	factors	that	affect	the	reproducible	formation	microsphere	coatings	including	solvent	effects,	administration	technique,	and	drying	conditions	[131].		
The	present	study	reports	the	effect	of	peptoid	chain	length	(and	in	turn	helicity)	as	well	as	pH	and	ionic	strength	on	the	formation	and	robustness	of	peptoid	microsphere	coatings.	The	morphology	of	the	microsphere	coatings	was	analyzed	via	SEM.	The	studies	show	that	variations	in	chain	length	lead	to	changes	in	microsphere	size	and	size	distribution.	The	morphology	of	microsphere	coatings	deteriorated	at	low	ionic	strengths	and	pH,	however	they	are	extremely	robust	at	physiological	conditions.		
8.2.	Materials	and	Methods	
8.2.1.	Materials	
(S)-methylbenzylamine	and	4-methoxybenzylamine	were	purchased	from	Acros	Organics	(Pittsburgh,	PA).	tert-butyl	N-(4-aminobutyl)carbamate	was	purchased	from	CNH	Technologies	Inc.	(Woburn,	MA).	MBHA	rink	amide	resin	was	purchased	from	NovaBiochem	(Gibbstown,	NJ).	Piperidine	was	purchased	from	Sigma-Aldrich	(St.	Louis,	
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MO).	Test	grade	silicon	wafers	were	purchased	from	University	Wafer	(South	Boston,	MA).	Poly-L-lysine,	amino	silane,	and	ultra	clean	glass	microarray	slides	were	purchased	from	Thermo	Scientific	(Pittsburgh,	PA).	Disuccinimidyl	suberate	(DSS)	was	purchased	from	Pierce	(Rockford,	IL,	USA).	All	other	reagents	were	purchased	from	VWR	(Radnor,	PA).	All	chemicals	were	used	without	further	modifications	unless	otherwise	specified.		
8.2.2.	Peptoid	Synthesis	
Peptoids	were	synthesized	via	the	submonomer	solid-phase	method	on	rink	amide	resin	[122].	The	resin	was	initially	swelled	with	dimethylformamide	(DMF),	and	the	Fmoc	protecting	group	on	the	resin	was	removed	using	a	20%	solution	of	piperidine	in	DMF.	The	resin-bound	secondary	amine	was	acylated	with	0.4	M	bromoacetic	acid	(BAA)	in	DMF,	in	the	presence	of	N,N’-diisopropyl	carbodiimide	(DIC),	mixing	for	1	minute.	Amine	sub-monomers	were	incorporated	via	an	SN2	nucleophilic	substitution	reaction	with	0.5M	primary	amine	in	DMF,	mixing	for	2	minutes.	The	two-step	bromoacetylation	and	nucleophilic	substitution	cycle	were	repeated	until	all	desired	side	chains	have	been	incorporated.	The	peptoid	was	cleaved	from	the	resin	using	a	mixture	of	95%	trifluoroacetic	acid	(TFA),	2.5%	water,	and	2.5%	triisopropylsilane.	The	acid	was	removed	using	a	Heidolph	Laborota	4001	rotating	evaporator	(Elk	Grove	Village,	IL).	The	peptoid	solution	was	lyophilized	to	a	powder	using	a	Labconco	lyophilizer	(Kansas	City,	MO).	The	peptoid	powder	was	diluted	to	a	concentration	of	~3	mg/ml	in	a	50:50	acetonitrile-water	solution.		
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8.2.3.	Purification	
Peptoids	were	purified	using	a	Waters	Delta	600	preparative	high-performance	liquid	chromatography	(HPLC)	instrument	(Milford,	MA)	with	a	Duragel	G	C18	150	×	20	mm	column	(Peeke	Scientific,	Novato,	CA)	and	a	linear	gradient	of	35-95%	solvent	B	(acetonitrile,	5%	water,	0.1%	TFA)	in	A	(water,	5%	acetonitrile,	0.1%	TFA),	over	60	minutes.		Peptoids	were	confirmed	to	be	>98%	pure	via	analytical	HPLC	(Waters	Alliance,	Milford,	MA)	with	a	Duragel	G	C18	150	×	2.1	mm	column	(Peeke	Scientific,	Novato,	CA)	using	a	linear	gradient	of	35	to	95%	solvent	D	(acetonitrile,	0.1%	TFA)	in	C	(water,	0.1%	TFA),	over	30	minutes.	Purified	peptoid	fractions	were	lyophilized	using	a	and	stored	as	a	powder	at	-20	°C.	
8.2.4.	Characterization	
Synthesis	was	confirmed	via	matrix	assisted	laser	desorption/ionization	time	of	flight	(MALDI-TOF)	mass	spectrometry	(Bruker,	Billerica,	MA).	Secondary	structure	was	confirmed	via	CD	spectrometry	using	a	Jasco	J-715	instrument	(Easton,	MD)	at	room	temperature	with	a	scanning	speed	of	20	nm/min	and	a	path	length	of	0.2	mm.	The	peptoid	was	dissolved	in	methanol	at	a	concentration	of	60	µM.	Each	spectrum	was	the	average	of	twenty	accumulations.	
8.2.5.	Peptoid	Microsphere	Coatings	
Peptoid	microspheres	were	prepared	by	dissolving	the	peptoid	in	a	4:1	(v/v)	ethanol/water	solution	at	a	concentration	of	5	mg/ml.	The	peptoid	solution	was	applied	using	a	pipette	onto	a	glass	surface	and	allowed	to	dry	at	room	temperature	and	60%	
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relative	humidity	for	an	hour.	Coating	morphologies	were	visually	assessed	using	a	Phillips	XL-30	environmental	scanning	electron	microscope	(SEM;	FEI,	Hillsboro,	OR)	at	the	Material	Characterization	Facility.	
8.2.6.	Microsphere	Analysis	
Particle	analysis	was	performed	using	ImageJ	software	(National	Institute	of	Health,	MD).	Noise	reduction	through	a	fast	Fourier	transform	(FFT)	band-pass	filter	normalization.	This	eliminates	low-	and	high-spatial	frequencies	and	transforms	the	original	SEM	images	to	a	two-dimensional	representation	of	its	frequencies.	The	images	were	converted	to	an	8-bit	grayscale	and	binarized	adjusting	the	white	and	black	threshold	to	optimize	particle	contrast	with	the	background.	Lastly,	a	standard	watershed	algorithm	was	used	to	separate	fused	markers.		
8.3.	Results	and	Discussion	
8.3.1.	Peptoid	Sequence	
The	peptoid	sequence	used	in	this	study	is	based	on	that	previously	shown	to	form	microspheres	[125]	and	is	referred	to	as	P3	(Figure	8.1.).	The	addition	of	chiral	aromatic	side	chains	in	two	faces	of	the	helix	sterically	induces	the	formation	of	a	helical	secondary	peptoid	structure	(Figure	8.1.).	The	third	face	of	the	peptoid	helices	allows	for	the	incorporation	of	more	ample	chemistries.	The	P3	sequence,	contains	side	chains	with	amine	and	methoxy	groups	to	increase	water	solubility,	as	partial	water	solubility	is	crucial	for	microsphere	formation.	The	amine	groups	facilitate	surface	attachment,	via	covalent	linkage	and	electrostatic	interactions.	To	analyze	the	effects	of	chain	length	on	microsphere	
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formation,	we	prepared	four	different	chain	lengths	inspired	in	the	P3	sequence	(Figure	8.1.)	used	in	previous	studies,	which	essentially	repeats	a	6-monomer	unit	sequence	twice.	For	such	studies,	we	synthesized	a	6	monomeric	unit	pepotid	sequence	(6mer),	a	12	monomer	sequence	(the	original	P3	12mer),	a	18	monomer	sequence	(18mer),	and	a	24	monomer	peptoid	sequence	(24mer)	all	assembled	by	repeating	the	6mer	peptoid	sequence	2,	3,	and	4	times	respectively.	
	Figure	8.1.	(A)	Linear	peptoid	sequence	to	the	n	reapeat	with	n	equal	to	1	(6mer	MW:	968),	2	(12mer	MW:	1919),	3	(18mer	MW:	2870),	and	4	(24mer	MW:	3821).	(B)	Helical	representation	of	the	three	faces	of	the	12mer	peptoid	sequence.		
8.3.2.	Chain	Length	Effects	
Previous	studies	have	shown	that	increasing	the	number	of	chiral	side	chains	in	a	peptoid	sequence	results	in	a	more	stable	helical	secondary	structure	[117].	In	this	study,	peptoid	chain	length	is	varied	to	alter	helicity	and	ultimately	microsphere	size.	We	hypothesize	that	larger	peptoid	sequences	exhibiting	tighter	helices	will	form	more	closely	packed	supramolecular	assemblies,	and	thus	smaller	microspheres,	while	shorter	peptoid	sequences	exhibiting	less	structured	helices	will	form	less	closely	packed	supramolecular	assemblies,	and	thus	larger	microspheres.	CD	spectra	(Figure	8.2.)	for	all	of	the	peptoids	
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exhibit	a	maximum	near	193	nm	and	two	minima	near	208	and	222	nm,	commonly	indicative	of	poly-proline	type-I-like	peptoid	helices	[121].	We	conclude	that,	analogously,	the	extent	of	helicity	increases	with	peptoid	length,	as	evidenced	by	the	increased	ratio	of	the	222	and	208	nm	peak	intensities	[177].		
		Figure	8.2.	Circular	dichroism	spectra	showing	a	poly-proline	type-I-like	helical	secondary	structure	for	the	peptoids	in	methanol	at	60	µM.		SEM	analysis	of	the	peptoid	coatings	formed	under	standard	conditions	show	that	microspheres	formed	for	the	12,	18,	and	24mer	peptoids	and	no	microspheres	were	observed	for	the	6mer	peptoid	(Figure	8.3.).	No	differences	were	observed	with	changes	in	these	variables,	and	the	6mer	peptoid	did	not	form	microspheres	under	any	conditions	tested.	The	average	microsphere	diameters	were	1.59	±	0.22,	1.19	±	0.24,	and	0.60	±	0.28	μm	for	the	12,	18,	and	24mer	peptoids,	respectively,	supporting	our	hypothesis	that	microsphere	size	decreases	with	increasing	helicity.	While	there	was	a	size	distribution	
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present	for	all	of	the	chain	lengths	(Figure	8.4.),	the	larger	microspheres	formed	by	the	12mer	peptoid	were	the	most	uniform.		
	Figure	8.3.	Chain	length	effect	on	microsphere	formation:	A)	6mer,	B)	12mer,	C)	18mer,	and	D)	24mer.	The	microspheres	were	formed	by	dissolving	the	peptoid	in	a	4:1	(v/v)	ethanol/water	solution	at	a	concentration	of	5	mg/ml.	The	peptoid	solution	was	applied	to	glass	surfaces	and	allowed	to	dry	at	room	temperature	and	60%	relative	humidity.		
	Figure	8.4.	Microsphere	size	distribution	present	for	each	peptoid	chain	length:	A)	12mer,	B)	18mer,	and	C)	24mer,	and	D)	24mer.		
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8.3.3.	Coating	Robustness	
In	order	to	be	practical	in	biosensor	applications,	the	peptoid	microsphere	coatings	must	be	robust	under	various	conditions.	The	robustness	of	the	peptoid	microspheres	were	assessed	in	conditions	common	to	ELISA	microarray	including	10	mg/mL	casein	in	phosphate-buffered	saline	(PBS;	pH	7.3,	ionic	strength	150	mM),	0.05%	Tween	in	PBS	(PBS-T;	pH	7.3,	ionic	strength	150	mM),	0.003%	hydrogen	peroxide	in	0.1M	sodium	borate	(pH	8.2,	ionic	strength	600	mM),	and	nanopure	water	(pH	~7,	ionic	strength	~0	mM).	The	microspheres	were	able	to	withstand	all	conditions	with	minimal	effect	to	morphology	and	total	coverage,	with	the	exception	of	water	(Figure	8.5.).	After	exposure	to	water	for	30	minutes	the	microspheres	appeared	to	disintegrate	and	lift	from	the	service.	While	the	peptoid	microspheres	appear	to	start	to	solubilize	in	water	after	only	30	minutes,	they	are	robust	in	PBS	for	up	to	2	months	(see	Figure	S8.1.	in	Supplemental	Information).	Based	on	these	preliminary	findings,	we	have	investigated	the	effects	of	pH	and	ionic	strength	on	peptoid	microsphere	coating	robustness.		
	Figure	8.5.	SEM	images	of	the	peptoid	microspheres	(A)	before	incubation,	(B)	after	24	hour	incubation	in	PBS,	(C)	after	30	minute	incubation	in	water	incubation	with	inset	(D)	showing	a	high	magnification	peptoid	microsphere.	The	microspheres	were	formed	by	dissolving	the	peptoid	in	a	4:1	(v/v)	ethanol/water	solution	at	a	concentration	of	5	mg/ml.	The	peptoid	solution	was	applied	to	glass	surfaces	and	allowed	to	dry	at	room	temperature	and	60%	relative	humidity.		
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pH.	In	order	to	determine	the	effect	of	solvent	pH	on	peptoid	microsphere	coating	robustness,	morphology	and	coating	coverage	was	assessed	by	SEM	following	incubation	in	PBS	and	water	at	different	pH	values.	Coatings	exposed	to	PBS	or	water	with	pH	of	7	or	greater	are	robust,	with	no	significant	differences	in	microsphere	morphology	or	coating	coverage	(Figure	8.6.	panels	A-E).	As	the	solvent	approaches	acidic	conditions	(pH	less	than	7),	the	microsphere	morphology	and	coating	coverage	deteriorate	(Figure	8.6.	panels	F-I).	This	observation	was	consistent	whether	the	pH	effect	was	analyzed	in	PBS	or	water	at	similar	pH	values	(see	Figure	S8.2.	in	Supplemental	Information).	While	we	do	not	anticipate	changes	in	pH	of	the	solvent	environment	to	change	the	charge	state	of	peptoid.	Acidic	conditions	increase	peptoid	solubility.	Peptoids	with	ionizable	side	chains	have	been	demonstrated	to	destabilize	in	response	to	pH-depenent	changes	in	aqueous	solvent	environment	[123]	[178].	It	would	be	interesting	to	complete	a	more	thorough	CD	studies	on	the	effects	of	pH	on	secondary	structure	for	our	particular	peptoid	sequences.	
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	Figure	8.6.	SEM	images	demonstrating	the	effect	of	pH	on	sphere	morphology	after	30	minutes	in	PBS,	pH	values	range	from:	A)	pH	11,	B)	pH	10,	C)	pH	9,	D)	pH	8,	E)	pH	7,	F)	pH	6,	G)	pH	5,	H)	pH	4,	and	I)	pH	11.		
Ionic	Strength.	The	effect	of	ionic	strength	on	peptoid	microsphere	coating	robustness	was	assessed	via	SEM	following	incubation	in	various	ionic	strength	solutions	(0-500	mM)	at	either	pH	6.7	(water)	or	pH	7.3	(PBS).	Following	incubation	in	water	solutions,	SEM	images	demonstrate	no	considerable	effect	on	microsphere	morphology	at	ionic	strengths	greater	than	150	mM	(Figure	8.7.	panels	A-C).	As	the	ionic	strength	decreases,	microsphere	morphology	and	coverage	begins	to	deteriorate	(Figure	8.7.	panels	D-F).		At	ionic	strengths	less	than	150	mM	the	microspheres	appear	to	fuse	together	and	as	ionic	strength	decreases	the	microspheres	detach	from	the	surface.	Experiments	evaluating	the	effect	of	ionic	strength	in	PBS	(pH	7.3)	demonstrate	similar	trends,	with	the	peptoid	microspheres	remaining	unaffected	at	ionic	strengths	above	150	mM	(Figure	8.8.).		
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As	compared	to	peptide	helices,	peptoid	helices	have	much	more	stable	conformational	assemblies.	As	a	result,	helical	peptiod	have	been	demonstrated	to	be	much	less	susceptible	to	their	solvent	conditions.	In	peptides,	increasing	the	ionic	strength	of	the	solvent	has	been	demonstrated	to	stabilize	secondary	structure	in	a	variety	of	ionic	polypeptides	by	screening	the	electrostatic	repulsion	between	side	chains	[179]	[180]	[181].	Strongly	charged	helical	peptides	are	completely	destabilized	in	low	ionic	strength	environments	[182].	Interestingly,	a	similar	dependence	has	been	observed	in	high-ionic	strength	solutions	in	peptoids	[133]	[178].	We	believe	that	the	screening	of	charge-charge	repulsive	interactions	at	higher	ionic	strengths	preserve	the	helical	secondary	that	is	crucial	for	microsphere	formation.		
	Figure	8.7.		SEM	images	demonstrating	the	effect	of	ionic	strength	on	sphere	morphology	after	30	minutes.	A)	500	mM	,	B)	250	mM,	C)	150	mM,	D)	100	mM,	E)	50	mM,	and	F)	0	mM	ionic	strength	in	water.		
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	Figure	8.8.		SEM	images	demonstrating	the	effect	of	ionic	strength	on	sphere	morphology	after	30	minutes.	A)	500	mM,	B)	250	mM,	and	C)	150	mM	ionic	strength	in	PBS.		
8.4.	Conclusion	
We	have	evaluated	the	use	the	effect	of	peptoid	chain	length	as	well	as	pH	and	ionic	strength	on	the	formation	and	robustness	of	peptoid	microsphere	coatings.	We	have	found	that	sphere	size	can	be	tuned	by	varying	peptoid	chain	length.	CD	spectra	as	a	function	of	peptoid	chain	length	suggests	that	larger	sequence	increase	the	degree	of	helicity.	We	believe	that	larger	peptoid	sequences	form	tighter,	more	stable	helices,	which	enable	the	formation	of	smaller	supramolecular	assemblies.	While	the	microsphere	deteriorated	at	low	ionic	strengths	and	pH,	the	coatings	display	outstanding	robustness	at	physiological	conditions.	Acidic	conditions	increase	the	peptoid	low	aqueous	solubility.	We	believe	that	solvent	counterions	at	higher	ionic	strengths	screen	the	electrostatic	repulsion	between	side	chains	and	stabilize	secondary	structure,	shielding	the	micropsheres.	
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8.6.	Supplemental	Information	
	Figure	S8.1.		SEM	images	demonstrating	the	robustness	of	the	microsphere	in	PBS	after	2	months.		
	Figure	S8.2.	SEM	images	demonstrating	the	effect	of	pH	on	sphere	morphology	after	30	minutes	in	water,	pH	values	range	from:	A)	no	incubation,	B)	pH	11,	C)	pH	8,	D)	pH	7,	E)	pH	6,	and	F)	pH	3.	
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9.	Conclusions	
The	search	for	non-invasive,	high-throughput,	and	cost-effective	tools	for	early	stage	disease	detection	has	led	to	the	development	of	biosensor	technologies	of	increasing	complexity.		Advances	in	biomarker	technologies	require	the	development	of	support	surfaces	that	allow	for	more	versatile	immobilization	procedures.	The	challenge	lies	in	designing	an	interface	that	accommodates	molecules	of	diverse	characteristics	in	a	manner	that	retains	their	innate	activities.	Surfaces	need	to	provide	biocompatible	and	bioresistant	interfaces,	that	offer	high	surface	areas	for	binding,	and	enables	the	incorporation	of	diverse	chemistries.	We	believe	that	the	use	of	peptoids	as	the	basis	for	the	deposition	of	uniform	microsphere	coatings	offers	a	promising	means	to	the	attainment	of	such	interfacial	characteristics.		
We	have	studied	the	variants	affecting	the	formation	of	the	peptoid	microspheres,	and	their	deposition	into	uniform	coatings.	We	have	found	that	varying	peptoid	chain	length	allows	for	the	rational	tuning	of	microsphere	size.	We	have	demonstrated	that	the	peptoid	microsphere	coatings	are	extremely	robust	for	applications	at	physiological	conditions.	We	have	evaluated	the	use	of	peptoid	microsphere	coatings	as	a	novel	surface	for	ELISA	microarrays.	The	peptoid-based	coatings	increase	the	surface	area	for	protein	binding,	and	allow	for	robust	chemistries	of	attachment.		While	the	coatings	exhibited	higher	background	fluorescence	and	coefficients	of	variation,	they	performed	well	in	terms	of	limits	of	detection	and	signal-to-noise	ratios	compared	to	some	of	the	best	microarray	surfaces	commercially	available.	We	believe	that	peptoid	microsphere	coatings	provide	a	robust,	biocompatible,	versatile	new	interface	that	can	be	easily	customized	in	design	and	
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surface	modified	for	a	wide	range	of	biosensor	applications.		
10.	Future	Work	
It	is	important	to	note	that	these	studies	were	in	many	cases	performed	under	very	particular	set	of	conditions.	Valuable	insight	that	could	that	could	elucidate	a	more	complete	understating	of	our	peptoid	sequence	likely	lies	in	the	synthesis	of	a	different	peptoid	sequence.	It	would	be	interesting	to	complete	a	more	thorough	study	of	the	effect	of	pH	and	ionic	strength	on	secondary	structure	and	its	effect	of	the	observed	morphological	changes.	A	more	hydrophilic	variant	of	our	P3	peptoid	would	likely	need	to	be	synthesized	for	CD	studies.	Similarly,	it	would	be	interesting	to	assess	whether	the	effects	seen	would	remain	for	peptoids	with	non-ionizable	side	chains.	As	well	as	assess	whether	different	acids	would	result	in	similar	morphological	variations.	It	would	be	valuable	to	assess	whether	differences	in	osmotic	pressure	are	responsible	for	the	changes	seen	at	different	ionic	strengths.	As	well	as	determine,	potentially	by	measuring	the	surfaces	zeta	potential	whether	the	charged	sidechains	are	preferentially	facing	the	outer	surface	of	the	microspheres.	The	covalent	immobilization	of	antibodies	on	the	surface	of	this	microspheres	via	the	amine	groups	suggests	of	their	surface	presence.	In	regard	to	the	use	of	the	peptoid	microsphere	coating	for	microarray	applications,	I	believe	there	is	considerable	room	for	improvement,	in	particular	by	further	optimizing	pre-treatment	and	blocking	buffers	in	order	to	reduce	background	fluorescence,	as	well	as	improve	spot	morphologies	and	further	raise	signal	intensities	upon	the	addition	of	different	additives,	such	as	glycerol,	to	the	printing	buffers.		
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13.	Appendix:	Submonomer	Structures		
(S)-Methylbenzylamine	
	
4-Methoxybenzylamine		
	
Tert-butyl	N-(4-aminobutyl)carbamate	
	
	
